<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">106699</article-id><article-id pub-id-type="doi">10.7554/eLife.106699</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.106699.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Chromosomes and Gene Expression</subject></subj-group></article-categories><title-group><article-title>Degradation of LMO2 in T cell leukaemia results in collateral breakdown of transcription complex partners and causes LMO2-dependent apoptosis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sereesongsaeng</surname><given-names>Naphannop</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7344-441X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Bataille</surname><given-names>Carole</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Russell</surname><given-names>Angela</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Bery</surname><given-names>Nicolas</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2643-3897</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="pa1">†</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Sialana</surname><given-names>Fernando J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9083-1657</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Choudhary</surname><given-names>Jyoti</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Miller</surname><given-names>Ami</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="pa2">‡</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Rabbitts</surname><given-names>Terence</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4982-2609</contrib-id><email>terry.rabbitts@icr.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043jzw605</institution-id><institution>Institute of Cancer Research, Division of Cancer Therapeutics</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>Department of Chemistry, Chemistry Research Laboratory, University of Oxford</institution></institution-wrap><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>Department of Pharmacology, University of Oxford</institution></institution-wrap><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>Weatherall Institute of Molecular Medicine, MRC Molecular Haematology Unit, University of Oxford</institution></institution-wrap><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043jzw605</institution-id><institution>Institute of Cancer Research</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Cooper</surname><given-names>Jonathan A</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/007ps6h72</institution-id><institution>Fred Hutch Cancer Center</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Cooper</surname><given-names>Jonathan A</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/007ps6h72</institution-id><institution>Fred Hutch Cancer Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="present-address" id="pa1"><label>†</label><p>Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France</p></fn><fn fn-type="present-address" id="pa2"><label>‡</label><p>Evotec, Abingdon, United Kingdom</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>12</day><month>12</month><year>2025</year></pub-date><volume>14</volume><elocation-id>RP106699</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2025-03-18"><day>18</day><month>03</month><year>2025</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2025-03-18"><day>18</day><month>03</month><year>2025</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.12.09.627495"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-08-06"><day>06</day><month>08</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.106699.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-10-14"><day>14</day><month>10</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.106699.2"/></event></pub-history><permissions><copyright-statement>© 2025, Sereesongsaeng et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Sereesongsaeng et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-106699-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-106699-figures-v1.pdf"/><abstract><p>LMO2 is an intrinsically disordered transcription factor activated in T cell leukaemia that is difficult to target. It forms part of a multi-protein complex that has bipartite DNA binding through heterodimeric basic-helix-loop-helix (bHLH) and GATA proteins. To determine if degradation of LMO2 in the context of T cell acute leukaemias (T-ALL) has therapeutic potential, a chimeric intracellular antibody has been developed fusing an anti-LMO2 single-domain variable region with one of three E3 ligases to create biodegraders. The intracellular binary interaction of these biodegraders with LMO2 leads to its proteasomal degradation but, in addition, concomitant loss of bHLH proteins that associate with LMO2 in the DNA-binding complex. Chemical compound surrogates of the intracellular antibody paratope (called antibody-derived [Abd] compounds) have been modified to create proteolysis targeting chimeras (PROTACs) for orthogonal assays of effects of LMO2 degradation. These form a ternary complex with LMO2 and E3 ligase in leukaemia cells that induces degradation of LMO2 and is also accompanied by loss of associated bHLH proteins. This is accompanied by T-ALL growth inhibition, alterations in proteins involved in cell cycling and instigation of apoptosis. These effects do not occur in the absence of LMO2. Our work demonstrates that degradation of LMO2 affects T-ALL, and the lead compounds can eventually be developed into drugs for patient treatment. Our work describes methods for drug discovery starting with antibody fragments.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>chromosomal translocation</kwd><kwd>transcription factor</kwd><kwd>intracellular antibody</kwd><kwd>PROTAC</kwd><kwd>biodegrader</kwd><kwd>T cell leukaemia</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0055acf80</institution-id><institution>Blood Cancer UK</institution></institution-wrap></funding-source><award-id>12051</award-id><principal-award-recipient><name><surname>Sereesongsaeng</surname><given-names>Naphannop</given-names></name><name><surname>Bataille</surname><given-names>Carole</given-names></name><name><surname>Bery</surname><given-names>Nicolas</given-names></name><name><surname>Miller</surname><given-names>Ami</given-names></name><name><surname>Rabbitts</surname><given-names>Terence</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/054225q67</institution-id><institution>Cancer Research UK</institution></institution-wrap></funding-source><award-id>CRUK PDF</award-id><principal-award-recipient><name><surname>Sereesongsaeng</surname><given-names>Naphannop</given-names></name><name><surname>Rabbitts</surname><given-names>Terence</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0055acf80</institution-id><institution>Blood Cancer UK</institution></institution-wrap></funding-source><award-id>19013</award-id><principal-award-recipient><name><surname>Sereesongsaeng</surname><given-names>Naphannop</given-names></name><name><surname>Bataille</surname><given-names>Carole</given-names></name><name><surname>Bery</surname><given-names>Nicolas</given-names></name><name><surname>Miller</surname><given-names>Ami</given-names></name><name><surname>Rabbitts</surname><given-names>Terence</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Antibody surrogate degraders of LMO2 indicate that transcription complexes are susceptible to drug discovery and are therefore druggable.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Chromosomal translocations are among the consistent somatic mutations that lead to cancer and to the maintenance of the malignancy by abnormal gene activation and/or creating fusion genes (<ext-link ext-link-type="uri" xlink:href="https://mitelmandatabase.isb-cgc.org/">https://mitelmandatabase.isb-cgc.org/</ext-link>) (<xref ref-type="bibr" rid="bib31">Rowley, 2013</xref>; <xref ref-type="bibr" rid="bib29">Rabbitts, 2009</xref>). These changes are found in all tumour types, and regulation of the tumour state is due to the translocation gene expressed proteins. In tumours of haematopoietic origin and some solid tumours, for instance, sarcomas, the translocation proteins are transcription factors that can have master regulator functions in tumourigenesis by disrupting differentiation programmes (<xref ref-type="bibr" rid="bib12">Cleary, 1991</xref>; <xref ref-type="bibr" rid="bib28">Rabbitts, 1991</xref>). While translocation proteins offer tumour-specific targets and are therefore attractive as therapeutic targets, where they are transcription factors, they are considered undruggable, or hard-to-drug. This is because they are intrinsically disordered proteins or have extensive disordered regions that make them difficult to handle in recombinant form and for which limited structural information is known.</p><p> In T cell acute leukaemias (T-ALL), there are a number of chromosomal translocations (<xref ref-type="bibr" rid="bib25">Pagliaro et al., 2024</xref>; <xref ref-type="bibr" rid="bib43">Williams et al., 1984</xref>), including those activating the <italic>LMO2</italic> gene by t(11;14)(p13;q11) (<xref ref-type="bibr" rid="bib8">Boehm et al., 1991</xref>; <xref ref-type="bibr" rid="bib32">Royer-Pokora et al., 1991</xref>). The LMO2 protein is a master regulator of haematopoiesis since mouse gene targeting showed that both primitive (<xref ref-type="bibr" rid="bib41">Warren et al., 1994</xref>) and definitive haematopoiesis fail with loss of the <italic>Lmo2</italic> gene (<xref ref-type="bibr" rid="bib45">Yamada et al., 1998</xref>). Further, this regulator function of LMO2 is shown by its role in remodelling of established vascular endothelial but not in de novo endothelial formation (<xref ref-type="bibr" rid="bib46">Yamada et al., 2000</xref>; <xref ref-type="bibr" rid="bib47">Yamada et al., 2022</xref>). This latter function has implications for targeting tumour angiogenesis. LMO2 is a transcription factor whose role in creating a multi-protein complex was first demonstrated in erythroid cells, and the LMO2 complex comprises LDB1, TAL1, E47, and GATA (<xref ref-type="bibr" rid="bib40">Wadman et al., 1997</xref>). Although LMO2 is a zinc-containing protein comprising two LIM domains, each with two LIM fingers, the protein does not appear to interact directly with DNA but rather bridges a multi-protein DNA-binding complex (<xref ref-type="bibr" rid="bib15">El Omari et al., 2013</xref>).</p><p>LMO2 is an intrinsically disordered protein (IDP) that defied production in recombinant form and it has been hard to study the cellular properties of the protein and the protein complex. We have described anti-LMO2 human single variable intracellular domain antibody (designed iDAb) that blocks the formation of the LMO2 protein complex when expressed in cells (<xref ref-type="bibr" rid="bib37">Tanaka et al., 2011</xref>) and discriminates the LMO family paralogues (<xref ref-type="bibr" rid="bib34">Sewell et al., 2014</xref>). In addition, we used a cell-based intracellular antibody competition assay to develop compounds to interfere with the LMO2-iDAb interaction and these small molecules that are surrogates of the iDAb paratope (<xref ref-type="bibr" rid="bib5">Bery et al., 2021</xref>) (antibody-derived [Abd] compounds). Further, chimeric intracellular antibodies could be engineered to carry warheads such as pro-caspase that cause proximity-induced, antigen-dependent apoptosis (<xref ref-type="bibr" rid="bib39">Tse and Rabbitts, 2000</xref>) and suggested that other fusion proteins could be designed to affect other cellular pathways such as proteolysis (<xref ref-type="bibr" rid="bib21">Lobato and Rabbitts, 2003</xref>). This was demonstrated using our anti-RAS iDAb for targeted protein degradation of KRAS (<xref ref-type="bibr" rid="bib4">Bery et al., 2020</xref>). As a means to study the LMO2 transcription complex in the context of T-ALL, we have produced two types of protein degradation mediators. In the first, an anti-LMO2 iDAb was directly fused with one of three different E3 ligases (herein called biodegraders) and in the second, an LMO2 iDAb paratope-derived Abd compound was altered to be two different proteolysis targeting chimeras (PROTACs) (<xref ref-type="bibr" rid="bib33">Sakamoto et al., 2001</xref>; <xref ref-type="bibr" rid="bib3">Békés et al., 2022</xref>; <xref ref-type="bibr" rid="bib26">Paiva and Crews, 2019</xref>; <xref ref-type="bibr" rid="bib11">Burslem and Crews, 2020</xref>). Treatment of T-ALL cells expressing LMO2, from chromosomal translocations or other promoter alterations, with these degraders showed rapid targeted protein degradation of the LMO2 transcription factor but also levels of TAL1 and E47 (members of the transcription complex; <xref ref-type="bibr" rid="bib40">Wadman et al., 1997</xref>) are reduced. These alterations in the LMO2 multi-protein complex cause inhibition of cell growth accompanied by initiation of programmed cell death. Therefore, targeting protein stability of the LMO2 complex shows the dependency of LMO2-positive T-ALL and that other proteins in the transcription factor complex can be disrupted by collateral degradation. LMO2 degraders are lead compounds for drug development for LMO2-positive T-ALL, and the approach is applicable to transcription factor complexes, including those involving IDPs.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>A biodegrader causes loss of LMO2 and collateral loss of TAL1/E47 bHLH</title><p>In our mouse models of LMO2 tumourigenesis, we observed that transgenic enforced thymus expression of Lmo2 (using CD2 promoter) but not Tal1 causes later onset, clonal T cell neoplasia, which arose earlier in double transgenic mice (<xref ref-type="bibr" rid="bib17">Larson et al., 1996</xref>). Expressing anti-LMO2 iDAb (a human VH segment) inhibited tumour growth in a transplantation model (<xref ref-type="bibr" rid="bib37">Tanaka et al., 2011</xref>). To assess the ability to degrade LMO2 by the ubiquitin proteasome system, we began to dissect the elements of interaction in the LMO2 complex by engineering chimeric intracellular antibodies where an E3 ligase was fused either at the N- or C-terminus of the iDAb to mediate binary interactions between iDAb-E3 ligase and LMO2 for ubiquitination of LMO2 and proteasomal degradation. Targeted protein degradation of LMO2 was observed when any of the six iDAb-E3 ligase proteins were expressed in HEK293T cells along with an LMO2-expressing plasmid. No detectable loss of control protein RAS was observed (or of the loading controls, cyclophilin-b, and β-actin). Conversely, using anti-RAS iDAb-CRBN or anti-KRAS DARPin-UBOX or anti-KRAS DARPin-VHL caused turnover of RAS but not LMO2 (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>).</p><p>We further investigated the LMO2 degradation in natural LMO2 expression settings (i.e. T-ALL lines) using a lentivirus that conditionally expresses anti-LMO2 iDAb VH576 fused to CRBN E3 ligase (designated TLCV2-iDAb-CRBN) via a doxycycline-inducible promoter (TLCV2; <xref ref-type="bibr" rid="bib2">Barger et al., 2019</xref>). CRBN was chosen in the inducible assay since thalidomide is commonly used in PROTAC chemistry, and this gave the opportunity to further evaluate LMO2 degradation by cereblon. This lentivirus was used to infect either Jurkat (lacking LMO2 expression), KOPT-K1 (<xref ref-type="bibr" rid="bib14">Dong et al., 1995</xref>), or P12-Ichikawa cells (<xref ref-type="bibr" rid="bib42">Watanabe et al., 1978</xref>) (expressing LMO2 after chromosomal translocations). The level of LMO2 expression after induction of the biodegrader was analysed by western blotting. LMO2 levels showed a marked decrease within 9 hr of iDAb-CRBN induction and continued for the 48 hr of analysis in LMO2-expressing cells (<xref ref-type="fig" rid="fig1">Figure 1A</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Lentivirally expressed biodegrader affects the LMO2 multi-protein complex in T cell lines.</title><p>(<bold>A</bold>) The T cell lines Jurkat (LMO2-), KOPT-K1 (LMO2+), and P12-Ichikawa (LMO2+) cells were infected with lentivirus packaging plasmids and transfer vector (TLCV2-VH576-L10-CRBN) for 16 hr followed by 2 μg/ml doxycycline induction for 9, 24, and 48 hr. Western blotting analysis was used to detect LMO2, endogenous CRBN, and VH576-L10-CRBN levels after lentivirus infection. α-Tubulin was used as an internal loading control for western blotting analysis. (<bold>B</bold>) The level of LMO2 and proteins associated with the LMO2 transcription complex (TAL1, E47, Lyl-1, GATA3, and LDB1) was determined after KOPT-K1 cells were infected with TLCV2-VH576-L10-CRBN followed by 2 μg/ml doxycycline induction for 9, 24, and 48 hr. Cyclophilin-b was used as an internal loading control.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Western blot data with label shows the effect of lentiviral expressed biodegrader to the LMO2 multi-protein complex in T cell lines.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106699-fig1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>Western blot raw data shows the effect of lentiviral expressed biodegrader to the LMO2 multi-protein complex in T cell lines.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106699-fig1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata3"><label>Figure 1—source data 3.</label><caption><title>Western blot data with label shows the level of LMO2 and proteins associaed with the LMO2 transcription complex.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106699-fig1-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata4"><label>Figure 1—source data 4.</label><caption><title>Western blot raw data shows the level of LMO2 and proteins associaed with the LMO2 transcription complex.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106699-fig1-data4-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106699-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>LMO2 protein degradation in HEK293T cells after transfection with biodegrader constructs.</title><p>HEK293T cells were co-transfected with 1 μg pEF-BOS-LMO2 and plasmids expressing different intracellular domain antibody (iDAb) LMO2-E3 ligase fusions for 24 hr. The amount of the iDAb LMO2-E3 ligase plasmids was titrated from 0 to 1.0 μg. pEF-BOS (vector plasmid) was used to equalise the amount of plasmid transfection to 2 µg. Western blotting analysis showing the expression of LMO2 in cells transfected with CRBN-iDAb LMO2 (<bold>A</bold>), iDAb LMO2-CRBN (<bold>B</bold>), anti-RAS iDAb-CRBN (<bold>C</bold>), UBOX-iDAb LMO2 (<bold>D</bold>), iDAb LMO2-UBOX (<bold>E</bold>), UBOX-anti-RAS DARPin (<bold>F</bold>), VHL-iDAb LMO2 (<bold>G</bold>), iDAb LMO2-VHL (<bold>H</bold>), and VHL-anti-RAS DARPin (<bold>I</bold>). The antibodies used for protein detection are shown to the right of each panel. The anti-FLAG and antimyc 9E10 antibodies detect the FLAG and myc tag on each iDAb-E3 ligase, the anti-CRBN antibody detects the transfected iDAb-CRBN in (<bold>A–C</bold>) and anti-VHL detects the transfected iDAb-VHL in (<bold>G–I</bold>). Loading control proteins were detected with either anti-cyclophilin-b or anti-β-actin.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Western blot data with label shows LMO2 protein degradation in HEK293T cells with different biodegrader contruct.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106699-fig1-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata2"><label>Figure 1—figure supplement 1—source data 2.</label><caption><title>Western blot raw data shows LMO2 protein degradation in HEK293T cells with different biodegrader contruct.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106699-fig1-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106699-fig1-figsupp1-v1.tif"/></fig></fig-group><p>The LMO2 protein is associated with a bipartite DNA-binding multi-protein complex, involving basic-helix-loop-helix (bHLH) proteins TAL1/SCL and E47 and GATA (<xref ref-type="bibr" rid="bib40">Wadman et al., 1997</xref>). We determined if other members of the complex could be degraded coincidentally with LMO2 using the anti-LMO2 biodegrader. KOPT-K1 cells, which express LMO2 from a t(11;14)(p13:q11) chromosomal translocation (<xref ref-type="bibr" rid="bib14">Dong et al., 1995</xref>), were infected with the lentiviral TLCV2-iDAb-CRBN, and the biodegrader expression was induced for 9, 24, and 48 hr with doxycycline. Protein extracts were analysed by western blotting using antibodies recognising various components of the LMO2 complex. Targeted protein degradation of LMO2 is observed throughout the course of the biodegrader induction, and we also observed a rapid degradation of the two associated bHLH proteins TAL1/SCL and E47. No evidence was found for associated turnover of another bHLH protein LYL1 or of the LMO2-associating protein LDB1 or GATA3 (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). This unexpected finding of the bHLH collateral degradation is unlikely to be due to off-target binding of the anti-LMO2 iDAb with TAL1 or E47.</p></sec><sec id="s2-2"><title>Control of LMO2 protein levels using chemical degraders</title><p>These results with the biodegraders demonstrate the degradability of endogenous LMO2 by E3 ligase-based molecules. The difficulty of the delivery of these macromolecules supported the subsequent development of small-molecule-based LMO2 degraders. To circumvent the problem of antibody delivery, we have previously developed a technology approach which uses antibody paratopes to select small-molecule surrogates (Abd technology) (<xref ref-type="bibr" rid="bib27">Quevedo et al., 2018</xref>). Employing this technology, an Abd chemical series that binds to LMO2 was identified that interferes with the protein complex in cells (<xref ref-type="bibr" rid="bib5">Bery et al., 2021</xref>). As a means to compare their cell-specific effects with the biodegraders, the Abd chemical compounds have been reformatted as PROTAC Abd degraders (<xref ref-type="bibr" rid="bib19">Li and Crews, 2022</xref>). We used Abd-L21 and Abd-L27 as starting points for the PROTAC design (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>) based on previously described SAR (<xref ref-type="bibr" rid="bib5">Bery et al., 2021</xref>), where a broad tolerance of a range of para-substituents on the right-hand side arene ring was found (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Similarly, on the left-hand side, meta-substituted arenes were preferred with a range of substituents tolerated. Piperazine was preferred to the imidazolidin-2-one, seen in Abd-L9 (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>), for activity, stability, and ease of synthesis, and was therefore selected for our PROTACs. Thiazole and oxazole were found to be interchangeable without any noticeable difference in activity, although the thiazole series was found to be easier to synthesise with higher chemical stability and better yields. It was decided to use a medium-length linker as a starting point, namely two PEG units for the VHL-binding ligand (<xref ref-type="bibr" rid="bib10">Buckley et al., 2012</xref>) and a six-carbon alkyl unit for the CRBN-binding ligand (<xref ref-type="bibr" rid="bib30">Remillard et al., 2017</xref>). Accordingly, two Abd E3 ligase ligand hetero-bifunctional molecules, designated Abd-VHL and Abd-CRBN, were synthesised with either the VHL or thalidomide E3 ligase ligand, respectively (<xref ref-type="fig" rid="fig2">Figure 2B and C</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>LMO2 antibody-derived (Abd) degraders and effects on cellular protein.</title><p>(<bold>A</bold>) Structure-activity observations of LMO2-binding compounds derived using intracellular domain antibody (iDAb) VH576 in competitive, cell-based BRET (designated Abd compounds) contributed to a general structure of the LMO2-binding compounds. Based on broad tolerance to chemical modification at position R’, two proteolysis targeting chimeras (PROTACs) were synthesised, one bearing the VHL ligand (Abd-VHL, <bold>B</bold>) and the other bearing thalidomide (the CRBN ligand) (Abd-CRBN, <bold>C</bold>). Each PROTAC thus comprises the LMO2-binding ligand, a linker and an E3 ligase ligand. (<bold>D–E</bold>) KOPT-K1 and Jurkat cells were treated with different concentrations of Abd degraders at 0, 5, 10, and 20 μM for 24 hr, protein extracts prepared and fractioned by SDS-PAGE followed by western blotting. Abd-CRBN was used on cells in (<bold>D</bold>) and Abd-VHL in (<bold>E</bold>). Cells treated with 1% DMSO were used as a control and β-actin was used as an internal loading control for the western blotting analysis. The viability of KOPT-K1 cells was treated with 15 μM Abd-CRBN (<bold>F</bold>) or 15 μM Abd-VHL (<bold>G</bold>) for 0, 2, 4, 6, and 24 hr, using CellTiter-Glo assay. Data are presented as a relative to luminescence at 0 hr, normalised to 100%. Determination of DC<sub>50</sub> values of Abd-CRBN (<bold>H</bold>) and Abd-VHL (<bold>I</bold>) after 24 hr treatment in KOPT-K1 was determined using CellTiter-Glo calculated by GraphPad Prism 9.0 software. All the values were presented as the average values relative to cell viability values in control (DMSO-treated cells) normalised to 100%. Data represent mean + SEM (n=3). Luciferase cell-based report assays were used to determine the degradation of the proteins after transfected HEK293T cells with different Renilla luciferase (Rluc8) reporter plasmids (pEF-LMO2-Rluc8, pEF-MAX-Rluc8, pEF-RHOBWT-FL, pEF-KRSWT-Fl-RLuc8, pEF-GFP2-Rluc8, pEF-ISL1-Rluc8, and pEF-Zn268) followed by Abd-CRBN (<bold>J</bold>) and Abd-VHL (<bold>K</bold>) treatment at 0, 10, and 20 μM for 24 hr. The potential degradation of pEF-Tal-Rluc8 (<bold>L</bold>) and pEF-LMO2-Rluc8 (<bold>M</bold>) was determined by luciferase cell-based report assays after the treatment with Abd-CRBN or Abd-VHL at 0, 10, and 20 μM for 24 hr. Data represent mean + SEM (n=3).</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Raw data of cell viability and percentage of cell viability after Abd-CRBN treatment in KOPT-K1.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-106699-fig2-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Raw data of cell viability and percentage of cell viability after Abd-VHL treatment in KOPT-K1.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-106699-fig2-data2-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2sdata3"><label>Figure 2—source data 3.</label><caption><title>Raw data of luminescence measurement after Abd-CRBN treatment in KOPT-K1 for 24 hr.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-106699-fig2-data3-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2sdata4"><label>Figure 2—source data 4.</label><caption><title>Raw data of luminescence measurement after Abd-VHL treatment in KOPT-K1 for 24 hr.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-106699-fig2-data4-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2sdata5"><label>Figure 2—source data 5.</label><caption><title>Raw data of luminescence measurement in reporter assay after Abd-CRBN treatment in KOPT-K1.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-106699-fig2-data5-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2sdata6"><label>Figure 2—source data 6.</label><caption><title>Raw data of luminescence measurement in reporter assay after Abd-VHL treatment in KOPT-K1.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-106699-fig2-data6-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2sdata7"><label>Figure 2—source data 7.</label><caption><title>Raw data of luminescence measurement of pEF-Tal1-Rluc8 in reporter assay.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-106699-fig2-data7-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2sdata8"><label>Figure 2—source data 8.</label><caption><title>Raw data of luminescence measurement of pEF-LMO2-Rluc8 in reporter assay.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-106699-fig2-data8-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106699-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Viability of Jurkat and KOPT-K1 cells after treatment with antibody-derived (Abd) compounds and Abd degraders.</title><p>(<bold>A</bold>) Chemical structures of LMO2 Abd compounds. (B) Jurkat and KOPT-K1 cells were treated at 20 μM of Abd compounds from 0 to 48 hr. Cell viability after the treatment was measured by counting viable cells after staining cells with Trypan Blue. (<bold>C</bold> and <bold>D</bold>) Cell viability was also determined using Trypan Blue after the treatment with different concentrations of Abd degrader proteolysis targeting chimera (PROTAC) compounds (0, 5, 10, and 20 μM) for 2, 6, and 24 hr. (<bold>E</bold> and <bold>F</bold>) CellTiter-Glo viability assays of Jurkat and KOPT-K1 cells treated with a single 20 μM dose of Abd-CRBN (<bold>E</bold>) or Abd-VHL (<bold>F</bold>) for up to 48 hr. All the values are presented as the average viable cells per ml. Data represent mean + SEM (n=3).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106699-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>LMO2 antibody-derived (Abd) degraders and effects on cellular proteins.</title><p>KOPT-K1 and Jurkat cells were treated with different concentrations of Abd-CRBN (<bold>A </bold>and <bold>B</bold>) or Abd-VHL (<bold>C </bold>and <bold>D</bold>) at 0, 5, 10, and 20 μM for 2 and 6 hr, proteins extracted and fractioned by SDS-PAGE followed by western blotting. β-Actin was used as a loading control for analysis.</p><p><supplementary-material id="fig2s2sdata1"><label>Figure 2—figure supplement 2—source data 1.</label><caption><title>Western blot data with label shows LMO2 level in Jurkat and KOPT-K1 after the treatment from 0-20 μM at 2 and 6 hr.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106699-fig2-figsupp2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s2sdata2"><label>Figure 2—figure supplement 2—source data 2.</label><caption><title>Western blot raw data shows LMO2 level in Jurkat and KOPT-K1 after the treatment from 0-20 μM at 2 and 6 hr.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106699-fig2-figsupp2-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106699-fig2-figsupp2-v1.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>Densitometry analysis of LMO2 protein expression.</title><p>Quantification of western blot data from <xref ref-type="fig" rid="fig2">Figure 2D–I</xref>. KOPT-K1 and Jurkat cells were treated with different concentrations of Abd-CRBN or Abs-VHL at 0, 5, 10, and 20 μM for 2, 6, and 24 hr. The densitometry values were determined by using Image Lab software. Data represent mean + SEM (n=3).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106699-fig2-figsupp3-v1.tif"/></fig><fig id="fig2s4" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 4.</label><caption><title>Dose response of T cell lines with antibody-derived (Abd) degraders.</title><p>T cells were treated with Abd-CRBN or Abd-VHL in a dose range from 0 to 25 μM for 24 hr. The effect on viability was measured using CellTiter-Glo assays at 24 hr in Jurkat, KOPT-K1, and MOLT-3 with Abd-CRBN (<bold>A–C</bold>) or with Abd-VHL (<bold>D–F</bold>). Data represent mean + SEM (n=3). EC<sub>50</sub> values were determined from dose-response curves generated using GraphPad Prism 9.0 software.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106699-fig2-figsupp4-v1.tif"/></fig><fig id="fig2s5" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 5.</label><caption><title>Longevity of responses of KOPT-K1 cells to single-dose treatment with antibody-derived (Abd) degraders.</title><p>Jurkat and KOPT-K1 cells were treated with 20 μM of Abd compounds and cultured from 0 to 72 hr. Western blot data of LMO2 and RAS expression in cells were treated with Abd-CRBN (<bold>A</bold>) and Abd-VHL (<bold>B</bold>). β-Actin was used as an internal loading control for western blotting analysis. Cell viability was determined using the CellTiter-Glo assay after the treatment with Abd-CRBN (<bold>C</bold>) and Abd-VHL (<bold>D</bold>) at points during the 72 hr. All the values are presented as the average luminescence values. Data represent mean + SEM (n=3).</p><p><supplementary-material id="fig2s5sdata1"><label>Figure 2—figure supplement 5—source data 1.</label><caption><title>Western blot data with label shows the longevity of responses of KOPT-K1 cells to single dose treatment.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106699-fig2-figsupp5-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s5sdata2"><label>Figure 2—figure supplement 5—source data 2.</label><caption><title>Western blot raw data shows the longevity of responses of KOPT-K1 cells to single dose treatment.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106699-fig2-figsupp5-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106699-fig2-figsupp5-v1.tif"/></fig><fig id="fig2s6" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 6.</label><caption><title>LMO2 levels and viability of KOPT-K1 cells treated with antibody-derived (Abd) degrader compounds and E3 ligase inhibitors.</title><p>The involvement of proteasome machinery was investigated in KOPT-K1 with proteasome inhibitors or by competing with free E3 ligase ligands. Western blot data show LMO2 expression in KOPT-K1 cells after the treatment with or without inhibitors followed by Abd compounds (<bold>A</bold>, <bold>C, E</bold>). Inhibitors used were the proteasome inhibitor epoxomicin (Epox) (0.8 μM), CRBN inhibitors (10 μM thalidomide [thal] and 10 μM lenalidomide [len]) (<bold>A</bold>, <bold>C</bold>), or free VHL ligand (<bold>E</bold>). Inhibitors were added for 2 hr prior to the treatment of 20 μM Abd-CRBN or Abd-VHL and further cultured for 24 hr. β-Actin was used as a loading control for analysis. Densitometry data of LMO2 in KOPT-K1 are presented as mean relative densitometry units, with standard deviation (<bold>B</bold>, <bold>D, F</bold>). After the treatment, cell viability was measured with Trypan Blue (<bold>G</bold>, <bold>H, and I</bold>). Data represent mean + SEM (n=3). KOPT-K1 cells were also treated with or without protein NEDDYlation inhibitor (10 μM MLN4941) for 2 hr prior to the treatment of Abd-CRBN (<bold>J</bold>) or Abd-VHL (<bold>K</bold>) for 24 hr. CellTiter-Glo assays (<bold>L </bold>and <bold>M</bold>) were used to measure viability, presented as relative to luminescence in DMSO-treated cells, and normalised to 100%. Data represent mean + SEM (n=3).</p><p><supplementary-material id="fig2s6sdata1"><label>Figure 2—figure supplement 6—source data 1.</label><caption><title>Western blot data with label shows LMO2 level of KOPT-K1 treated with Abd compounds and inhibitors.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106699-fig2-figsupp6-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s6sdata2"><label>Figure 2—figure supplement 6—source data 2.</label><caption><title>Western blot raw datashows LMO2 level of KOPT-K1 treated with Abd compounds and inhibitors.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106699-fig2-figsupp6-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106699-fig2-figsupp6-v1.tif"/></fig></fig-group><p>The selectivity of the chemical degraders was tested by comparing T cell viabilities when treated with Abd-VHL and Abd-CRBN or the starting Abd compounds. The result showed that reformatting the LMO2 Abd compounds as PROTACs improved selectivity of LMO2-expressing cells compared to non-expressor ones. This difference was clearer when titrating the Abd-VHL and Abd-CRBN compounds over a concentration range during a 24 hr assay period. Jurkat (LMO2 negative) were largely unaffected, while KOPT-K1 (LMO2 positive) showed loss of viability with increased PROTAC concentration, which is an effect sustained over 48 hr (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>).</p><p>The effect of the Abd-CRBN or Abd-VHL compounds on LMO2 protein levels was then assessed in dose response in KOPT-K1 and Jurkat cells. Cells were treated with a single dose of the compound, ranging from 0 to 20 µM for 2, 6, or 24 hr followed by analysis of protein levels by western blotting analysis and cell viability. At 24 hr treatment, LMO2 levels are reduced by either Abd-CRBN (<xref ref-type="fig" rid="fig2">Figure 2D</xref>) or Abd-VHL (<xref ref-type="fig" rid="fig2">Figure 2E</xref>), whereas control protein RAS levels are unaffected. There is also a progressive loss of LMO2 protein from 6 hr onwards up to the end point of 24 hr (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref> and quantified by densitometry, <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>). These findings were paralleled with loss of cell viability over the 24 hr period when KOPT-K1 cells were treated with 15 μM of either compound (<xref ref-type="fig" rid="fig2">Figure 2F–I</xref>) showing the half-maximal effective concentration (EC<sub>50</sub>) in KOPT-K1 was 14 and 12 μM for Abd-CRBN and Abd-VHL, respectively. The EC<sub>50</sub> values were in a comparable range to MOLT-3 cells (another LMO2-expressing cell line) compared to Jurkat cells that are resistant to either compound (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4</xref>). The longevity of degradation was followed using western blotting and CellTitre-Glo assays (<xref ref-type="fig" rid="fig2s5">Figure 2—figure supplement 5</xref>). LMO2 was lost in KOPT-K1 during the 72 hr of cell culture after a single dose of compounds, while little or no effect was observed in the LMO2 non-expressing Jurkat cells range.</p><p>The possible effect of the compounds on non-LMO protein controls was assessed using a luciferase cell-based report assay (<xref ref-type="fig" rid="fig2">Figure 2J and K</xref>). Fusions with Renilla luciferase of various baits were expressed in HEK293T cells, including the LIM protein ISL1 and the zinc finger proteins Zn268, and luciferase levels determined after treatment with the PROTAC compounds (0–20 μM) for 24 hr. Only the loss of luciferase in the positive control LMO2-Rluc8 fusion was observed. In addition, confirmation that the specific involvement of the Abd-CRBN or Abd-VHL to the proteasome machinery in the LMO2 turnover was confirmed by using either proteasome inhibitors or competing the Abd degraders with the respective free E3 ligase ligands (<xref ref-type="fig" rid="fig2s6">Figure 2—figure supplement 6</xref>). Furthermore, TAL1 protein was fused to Renilla luciferase to investigate possible cross-reaction of the LMO2 PROTAC compounds with TAL1. After treatment with either of the PROTACs compounds (0–20 μM) for 24 hr, the luciferase level does not reduce in TAL1-Rluc8 (<xref ref-type="fig" rid="fig2">Figure 2L</xref>), whereas a reduction of luciferase signal in the positive control LMO2-Rluc8 fusion was observed (<xref ref-type="fig" rid="fig2">Figure 2M</xref>). This result suggests that the collateral degradation of TAL1/SCL and of E47 is due to biological effects beyond simple protein-compound interaction, as also found with the application of the biodegrader.</p></sec><sec id="s2-3"><title>Loss of LMO2 protein also affects partner proteins in the transcription complex</title><p>Lentiviral infection of KOPT-K1 cells expressing an LMO2 biodegrader showed collateral loss of TAL1 and E47 proteins with LMO2 (<xref ref-type="fig" rid="fig1">Figure 1</xref>). The bystander degradation was not evident for other members of the transcription complex. To gain further insights into this finding, the effect of the Abd-CRBN and Abd-VHL compounds was assayed with two LMO2-expressing cell lines (KOPT-K1 and CCRF-CEM) compared with two non-expressors (Jurkat and DND-41) (<xref ref-type="fig" rid="fig3">Figure 3</xref>). A similar pattern of LMO2 degradation was observed in the two expressing lines as we had first found with expressed biodegrader from the lentivirus. Allied to this, the loss of both TAL1 and E47 proteins is dose-dependent (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), while there was no detectable loss of LYL1 (another T-ALL implicated bHLH protein), GATA3, or LDB1. Importantly, there was no apparent loss of these proteins in the two LMO2-non-expressing T cell lines. These results suggested that the proteolysis of TAL1 and E47 depended on degradation of LMO2 (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). The loss of LMO2, TAL1, and E47 occurs rapidly as protein loss is observed in as little as 2–4 hr after treatment (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). The involvement of the proteasome was confirmed by the inhibition of Abd-CRBN and Abd-VHL by epoxomicin in both KOPT-K1 and CCRF-CEM (<xref ref-type="fig" rid="fig3">Figure 3D</xref>) and requirement for E3 ligase by inhibition with the respective free ligand.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Proteins associated within the LMO2 transcription complex are co-degraded with the LMO2 proteolysis targeting chimeras (PROTACs).</title><p>LMO2-expressing (KOPT-K1 and CCRF-CEM) and non-expressing T cells (Jurkat and DND-41) were treated with antibody-derived (Abd) degraders, and protein extracts were prepared for western blot, detecting LMO2, TAL1, E47, Lyl-1, GATA3, LDB1 proteins (cyclophilin-b was used as an internal loading control) after cells were treated with different concentrations of Abd degraders at 0, 5, 10, 15, and 20 μM for 24 hr. (<bold>A</bold>) Western blotting analysis with KOPT-K1 and CCRF-CEM extracts and (<bold>B</bold>) western blotting analysis with Jurkat and DND-41 extracts. (<bold>C</bold>) KOPT-K1 and CCRF-CEM were treated with Abd degraders at 20 μM for 2, 4, 6, and 24 hr. Western blotting analysis data show LMO2, TAL1, and E47 proteins expression in KOPT-K1 and CCRF-CEM that was affected by treatment. (<bold>D</bold>) The involvement of proteasome machinery in protein complex degradation was investigated in KOPT-K1 and CCRF-CEM with either proteasome inhibitors or by competing the potential of the Abd degraders with free E3 ligase ligand. Western blot data show LMO2, TAL1, and E47 expression in KOPT-K1 and CCRF-CEM after the treatment with or without inhibitors followed by Abd compounds. Inhibitors used were the proteasome inhibitor epoxomicin (0.8 μM), or CRBN inhibitors (10 μM thalidomide) or free VHL ligand. Cyclophilin-b was used as an internal loading control for western blotting analysis.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Western blot data with label shows ptoteins associated within the LMO2 transcription complex in KOPT-K1 and CCRF-CEM.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106699-fig3-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>Western blot raw data shows ptoteins associated within the LMO2 transcription complex in KOPT-K1 and CCRF-CEM.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106699-fig3-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata3"><label>Figure 3—source data 3.</label><caption><title>Western blot data with label shows ptoteins associated within the LMO2 transcription complex in Jurkat and DND-41.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106699-fig3-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata4"><label>Figure 3—source data 4.</label><caption><title>Western blot raw data shows ptoteins associated within the LMO2 transcription complex in Jurkat and DND-41.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106699-fig3-data4-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata5"><label>Figure 3—source data 5.</label><caption><title>Western blot data with label shows ptoteins associated within the LMO2 transcription complex in KOPTK1- and CCRF-CEM after treated with Abd-degraders at 20 μM.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106699-fig3-data5-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata6"><label>Figure 3—source data 6.</label><caption><title>Western blot raw data shows ptoteins associated within the LMO2 transcription complex in KOPTK1- and CCRF-CEM after treated with Abd-degraders at 20 μM.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106699-fig3-data6-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata7"><label>Figure 3—source data 7.</label><caption><title>Western blot data with label shows the involvement of proteasome machinery in protein complex degradation.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106699-fig3-data7-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata8"><label>Figure 3—source data 8.</label><caption><title>Western blot raw data shows the involvement of proteasome machinery in protein complex degradation.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106699-fig3-data8-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106699-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Half-lives of LMO2 and LMO2 protein complex in KOPT-K1 cells.</title><p>Western blot data showed LMO2 and LMO2 protein complex (TAL1, E47, LYL1, LDB1, and GATA3) level after the treatment with 20 μg/ml cycloheximide from 0 to 24 hr (<bold>A</bold>). The level of protein remaining is presented as a relative to protein level at 0 hr (<bold>B</bold>). Data represent mean + SEM (n=3).</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Western blot data with label shows half-lives of LMO2 and LMO2 protein complex in KOPT-K1.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106699-fig3-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3s1sdata2"><label>Figure 3—figure supplement 1—source data 2.</label><caption><title>Western blot raw data shows half-lives of LMO2 and LMO2 protein complex in KOPT-K1.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106699-fig3-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106699-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>The LMO2 transcription complex indicating lysine residues in the basic-helix-loop-helix (bHLH) heterodimer for potential lysine ubiquitination.</title><p>The crystal structure of the LMO2-TAL1-E47 complex, adapted from <xref ref-type="bibr" rid="bib15">El Omari et al., 2013</xref>, is shown with LMO2 contacting the LID domain of LDB1, the TAL1 and E47 bHLH domains, and DNA. LMO2 is shown in grey; the VH576 interaction domain in pink (<xref ref-type="bibr" rid="bib34">Sewell et al., 2014</xref>); LID in orange; TAL1 in blue, and E47 in green. Lysine residues in TAL1 and E47 are in yellow and salmon, respectively.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106699-fig3-figsupp2-v1.tif"/></fig></fig-group></sec><sec id="s2-4"><title>The degradation of LMO2 interferes with cell growth, affecting proteins involved in proliferation</title><p>The potential effect of LMO2 protein loss was studied using the panel of cell lines expressing LMO2 (KOPT-K1, PF-382, P12-Ichikawa, CCRF-CEM, MOLT-16, and LOUCY) by simultaneously monitoring protein turnover and cell growth. Cells were treated with a single dose of either LMO2 PROTAC and analysed by western blot (<xref ref-type="fig" rid="fig4">Figure 4A–F</xref>). The western blot results showed that LMO2 degradation was observed to have occurred and was sustained for 48 hr. In this time frame, we did not find any evidence of loss of RAS proteins or β-actin controls.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Loss of LMO2 protein inhibits T cell acute leukaemia (T-ALL) cell growth.</title><p>LMO2-expressing T cells were treated with 20 μM antibody-derived (Abd)-CRBN or Abd-VHL for 24 and 48 hr, and protein extracts were prepared for western blot to detect LMO2 protein, RAS protein as negative control, and β-actin was used as an internal loading control. Western blotting analysis data show LMO2 expression in KOPT-K1 (<bold>A</bold>), PF-382 (<bold>B</bold>), P12-Ichikawa (<bold>C</bold>), CCRF-CEM (<bold>D</bold>), MOLT-16 (<bold>E</bold>), and LOUCY (<bold>F</bold>) that was affected by treatment with the LMO2 proteolysis targeting chimera (PROTAC) compounds. Comparative cell numbers were determined from increase in viability determined using the CellTiter-Glo assay. Data represent mean + SEM (n=3). LMO2-expressing cell lines tested were KOPT-K1 (<bold>G</bold>, t(11;14)(p13;q11)), PF-382 (<bold>H</bold>), P12-Ichikawa (<bold>I</bold>, t(11;14)(p13;q11)), CCRF-CEM (<bold>J</bold>), MOLT-16 (<bold>K</bold>), and LOUCY (<bold>L</bold>). LMO2 non-expressing T cells were also treated with 20 μM Abd-CRBN or Abd-VHL for 24 and 48 hr after which relative luminescence was determined using the CellTiter-Glo assay. Cells tested were Jurkat (<bold>M</bold>), DND-41 (<bold>N</bold>), ALL-SIL (<bold>O</bold>), SUPT-1 (<bold>P</bold>), and RPMI8402 (<bold>Q</bold>). Data represent mean + SEM (n=3).</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Western blot data with label shows the loss of LMO2 expression in T-ALL cells.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106699-fig4-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Western blot raw data shows the loss of LMO2 expression in T-ALL cells.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106699-fig4-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata3"><label>Figure 4—source data 3.</label><caption><title>Raw data of luminescence measurement from CellTiter-Glo assay in T-ALL cells after the treatment of Abd-CRBN and Abd-VHL for 24 and 48 hr.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-106699-fig4-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106699-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Verification of LMO2 non-expressing T cell lines.</title><p>Five human T cell lines were verified by western analysis of total protein extracts and probed with anti-LMO2, anti-RAS, and β-actin as an internal loading control. No LMO2 was detectable. In addition, off-target effects, as determined by RAS protein levels, of the antibody-derived (Abd)-CRBN and Abd-VHL were tested by treating the cells with 20 μM Abd degraders for 24 and 48 hr followed by western blotting.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Western blot data with label shows the verification of LMO2 non-expressing T-cells.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106699-fig4-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata2"><label>Figure 4—figure supplement 1—source data 2.</label><caption><title>Western blot raw data shows the verification of LMO2 non-expressing T-cells.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106699-fig4-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106699-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Reverse transcription-PCR (RT-PCR) analysis of the human T cell acute leukaemia (ALL) panel.</title><p>Agarose gel electrophoresis of LMO1 (<bold>A</bold>), LMO2 (<bold>B</bold>), and KRAS (<bold>C</bold>) PCR products from the different human T cell lines (KOPT-K1, P12-Ichikawa, MOLT-3, PF-382, Jurkat, DND-41, and ALL-SIL). Lane M represents a 1 kb ladder.RT-PCR primer sequences. LMO1: PCR product 410 bp Forward <named-content content-type="sequence">GATCCAGCCCAAAGGGAAGCAG</named-content> Reverse <named-content content-type="sequence">GATAAAGGTGCCATTGAGCTG</named-content> LMO2: PCR product 220 bp Forward <named-content content-type="sequence">GATTCCTCGGCCATCGAAAGG</named-content> Reverse <named-content content-type="sequence">GATGTTTGTAGTAGAGGCGCCG</named-content> KRAS: PCR product 249 bp Forward <named-content content-type="sequence">GATATGACTGAATATAAACTTGTGGTAG</named-content> Reverse <named-content content-type="sequence">GATGGCAAATACACAAAGAAAGC.</named-content></p><p><supplementary-material id="fig4s2sdata1"><label>Figure 4—figure supplement 2—source data 1.</label><caption><title>Agarose gel data with label shows PCR products from RT-PCR analysis of the human T-ALL cells.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106699-fig4-figsupp2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s2sdata2"><label>Figure 4—figure supplement 2—source data 2.</label><caption><title>Agarose gel raw data shows PCR products from RT-PCR analysis of the human T-ALL cells.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106699-fig4-figsupp2-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106699-fig4-figsupp2-v1.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Confirmation of chromosomal translocation in KOPT-K1 tissue culture cells.</title><p>The human T cell acute leukaemia (T-ALL) cells carry an LMO2 activating chromosomal translocation t(11;14)(p13;q11). The gPCR forward primers were designed to bind different 3’-ends of the breakpoint region, and the reverse primer was designed to bind at 5’-ends of the breakpoint region (<bold>A</bold>). Agarose gel electrophoresis was used to evaluate the PCR products (<bold>B</bold>), the different size of PCR products is shown in lanes 1 and 2. Lane M represents a 1 kb marker ladder. (<bold>C</bold>) The sequence of the genomic PCR primers was derived from the published breakpoint (<xref ref-type="bibr" rid="bib14">Dong et al., 1995</xref>) and the relevant germline sequences of chromosomes 11 and 14.</p><p><supplementary-material id="fig4s3sdata1"><label>Figure 4—figure supplement 3—source data 1.</label><caption><title>Agarose gel data with label shows PCR products to confirm the chromosomal translocation in KOPT-K1.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106699-fig4-figsupp3-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s3sdata2"><label>Figure 4—figure supplement 3—source data 2.</label><caption><title>Agarose gel raw data shows PCR products to confirm the chromosomal translocation in KOPT-K1.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106699-fig4-figsupp3-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106699-fig4-figsupp3-v1.tif"/></fig></fig-group><p>Comparing the effects on growth of cells treated with Abd-CRBN or Abd-VHL showed an inhibitory effect on T cell growth if LMO2 is expressed (a significant reduction [p&lt;0.001], <xref ref-type="fig" rid="fig4">Figure 4G–L</xref>), whereas T cells without LMO2 (Jurkat, DND-41, ALL-SIL, SUPT-1, and RPMI8402) are largely unaffected (<xref ref-type="fig" rid="fig4">Figure 4M–Q</xref>). The absence of LMO2 protein was confirmed by western blotting, RT-PCR analysis (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplements 1</xref>–<xref ref-type="fig" rid="fig4s2">2</xref>), and genomic sequencing (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>), and those expressing LMO1 were confirmed by RT-PCR. RPMI8402 has an LMO1 chromosomal translocation t(11;14)(p15;q11) from which <italic>LMO1</italic> was cloned (<xref ref-type="bibr" rid="bib7">Boehm et al., 1988</xref>; <xref ref-type="bibr" rid="bib23">McGuire et al., 1989</xref>). The small effects observed at 48 hr may be attributable to off-target toxicity.</p><p>Given the short time of exposure to the Abd PROTAC compounds (24 hr) to impair LMO2-positive T-ALL cell growth, we performed proteomic analysis of cells treated with Abd-VHL to ascertain the resultant changes to the cell composition. Proteomic data were obtained in an analysis of Abd-VHL treated in KOPT-K1 (LMO2 expressor), Jurkat (non-expressor) and RPMI8402 (non-expressor) cells. After the treatment of 15 μM Abd-VHL for 24 hr, the effect on the level of LMO2 was determined using liquid chromatography-mass spectrometry (LC-MS) with a targeted MS2 method (<xref ref-type="fig" rid="fig5">Figure 5A</xref>) and western blotting (<xref ref-type="fig" rid="fig5">Figure 5B</xref>), which confirmed the significant reduction of LMO2 after the treatment in KOPT-K1. We collected total proteome dataset and conducted Gene Ontology (GO) and KEGG pathway analyses using rank-based Gene Set Enrichment Analysis (GSEA) across the three cell lines and visualised the resulting enrichment scores in a heatmap (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Several pathways are affected after the treatment with Abd-VHL, even in the two cell lines that do not express LMO2. Most importantly, proteins related to cell division appear in the top 10 significantly affected pathways in KOPT-K1, while this effect does not appear in Jurkat and RPMI8402, consistent with cell growth data in KOPT-K1. Further, the average fold change (log<sub>2</sub>FC) in KOPT-K1 (<xref ref-type="fig" rid="fig5">Figure 5D</xref>) and Jurkat (<xref ref-type="fig" rid="fig5">Figure 5E</xref>) was represented as volcano plots, indicating that the total significantly changed proteins in KOPT-K1 is higher than Jurkat cells. To specify the effect of the Abd-VHL treatment to proteins changed in KOPT-K1, the proteins significantly increased or decreased compared to Jurkat cells are presented in <xref ref-type="fig" rid="fig5">Figure 5D</xref> and tabulated in <xref ref-type="fig" rid="fig5">Figure 5F</xref> (and in <xref ref-type="supplementary-material" rid="fig5sdata3">Figure 5—source data 3</xref>). The result showed that those significantly down-regulated proteins in KOPT-K1 relate to cell division pathway and some aspects of ubiquitination, while most proteins in Jurkat cells are unchanged. Overall, these results help explain why treatment with Abd-VHL has an effect on cell division in the LMO2-expressing cells.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Proteomic profiling of T cell acute leukaemia (T-ALL) cells after treatment with antibody-derived (Abd) proteolysis targeting chimera (PROTAC) degrader.</title><p>LMO2-expressing T cells (KOPT-K1) and LMO2 non-expressing T cells (Jurkat and RPMI8402) were treated in duplicate with 15 μM Abd-VHL for 24 hrs. (<bold>A</bold>) Floating bar plots of LMO2 protein levels measured by targeted proteomics in control (DMSO treated) (grey bars) and Abd-VHL treated (red bars) in KOPT-K1, Jurkat, and RPMI8402 cells. (<bold>B</bold>) Western blotting analysis of LMO2 levels in KOPT-K1 cells when treated with DMSO only and Abd-VHL for 24 hr. β-Actin protein detection was used as an internal loading control for western blotting analysis. (<bold>C</bold>) Heatmap displaying enriched terms from Gene Set Enrichment Analysis (GSEA) in KOPT-K1, Jurkat, and RPMI8402 cells after Abd-VHL treatment compared to control treatment (DMSO), based on global proteomics analysis. The enrichment score ranges from –2.5 (blue) to 2.5 (yellow). (<bold>D and E</bold>) Volcano plot of proteomic changes following Abd-VHL treatment compared to control treatment (DMSO) in KOPT-K1 (<bold>D</bold>) and Jurkat (<bold>E</bold>). The plots are based on the fold change (log<sub>2</sub>FC) and p-value (–log<sub>10</sub>(p-value)). Respectively, the yellow or grey circles indicate proteins with statistically significant or non-significant up-regulation/down-regulation. The cut-off for the volcano plots is log<sub>2</sub>FC = 0.585, p-value = 0.05. (<bold>F</bold>) A tabulation of statistically significant proteins in KOPT-KI, represented as yellow circles (<bold>D</bold>) compared to Jurkat cells. The data are presented as fold change (log<sub>2</sub>FC) and p-value (–log<sub>10</sub>(p-value)). The source data are available as <xref ref-type="supplementary-material" rid="fig5sdata3">Figure 5—source data 3</xref>.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Western blot data with label shows LMO2 level in KOPT-K1 after treated with DMSO and Abd-VHL for 24 hr.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106699-fig5-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>Western blot raw data shows LMO2 level in KOPT-K1 after treated with DMSO and Abd-VHL for 24 hr.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106699-fig5-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata3"><label>Figure 5—source data 3.</label><caption><title>Proteins reduced by treatment of KOPT-K1 cells with Abd-VHL.</title><p>Proteomic data showed the significant downregulated proteins in KOPT-K1 cells when treated with AbdVHL compared to control treatment (DMSO) and their functions related to cell division. Proteins shown based on the fold change (log2FC) and p-value.</p></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-106699-fig5-data3-v1.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106699-fig5-v1.tif"/></fig></sec><sec id="s2-5"><title>Loss of the LMO2 protein complex initiates apoptosis</title><p>We investigated whether LMO2 protein degradation in the T-ALL cell lines resulted in programmed cell death that accompanies growth inhibition effects. KOPT-K1 or Jurkat cells were treated with a single 20 μM dose of either Abd-CRBN or Abd-VHL for up to 30 hr and caspase 3/7 activation determined at the various time points. Increased levels of caspases were found in LMO2-expressing KOPT-K1 treated with either Abd compound, rising 10-fold (from 23,325 RLU at 4 hr to 228,865 RLU at 30 hr) using Abd-CRBN and 25-fold increase (from 19,460 RLU at 4 hr to 476,843 RLU at 30 hr) using Abd-VHL (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). This rise in activated caspases mirrors loss of LMO2 as judged by western blotting analysis (<xref ref-type="fig" rid="fig6">Figure 6B</xref>) and with appearance of cleaved caspase 3, cleaved caspase 7, and cleaved poly(ADP-ribose) polymerase (PARP). The increase of caspase 3/7 activity in KOPT-K1 cells treated with Abd-CRBN is lower than observed with Abd-VHL, reflected by relatively low levels of protein detected in western blot.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Caspase and poly(ADP-ribose) polymerase (PARP) cleavage in cells after treatment with antibody-derived (Abd) degraders indicative of apoptosis initiation.</title><p>KOPT-K1 and Jurkat cells were treated with Abd-CRBN or Abd-VHL and effects on viability and programmed cell death were analysed at different times. (<bold>A</bold>) Time course of progressive expression of caspases after the treatment with compounds was assayed for caspase 3/7 levels using Caspase-Glo 3/7. Cells were treated with 20 μM Abd-CRBN or Abd-VHL followed by cell culture up to 30 hr. Cells treated with 1% DMSO in culture medium were used as a control. Data represent mean + SEM (n=3). KOPT-K1 and Jurkat cells were treated with 20 μM Abd-CRBN (<bold>B</bold>) or Abd-VHL (<bold>C</bold>) and cultured for 24 or 48 hr. Cell extracts were made and proteins subjected to western blotting analysis with specific antibodies for detection of LMO2, caspase 3, cleaved caspase 3, caspase 7, cleaved caspase 7, PARP, and cleaved PARP. β-Actin protein detection was used as an internal loading control for western blotting analysis.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Western blot data with label shows the caspase and PARP cleavge in Jurkat and KOPT-K1 after treated with Abd-CRBN or Abd-VHL for 24 and 48 hr.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106699-fig6-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><label>Figure 6—source data 2.</label><caption><title>Western blot raw data shows the caspase and PARP cleavge in Jurkat and KOPT-K1 after treated with Abd-CRBN or Abd-VHL for 24 and 48 hr.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106699-fig6-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata3"><label>Figure 6—source data 3.</label><caption><title>Raw data of caspase3/7 level after the treatment with 20 μM Abd-CRBN or Abd-VHL.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-106699-fig6-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106699-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Caspase 7 and cleaved caspase 7 in Jurkat and KOPT-K1 cells after the treatment of doxorubicin.</title><p>Western blot data showed caspase 7 and cleaved caspase 7 after the treatment with 1 μM doxorubicin from 0 to 48 hr. At 48 hr treatment, doxorubicin at 1 μM induced 100% cell death in KOPT-K1 cells (A). Cell viability after the treatment at 4, 6, 12, 20, 24, and 30 hr in Jurkat and KOPT-K1 cells was determined using CellTiter-Glo assay (B). Data represent mean + SEM (n=3).</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>Western blot data with label shows the expression of caspase 7 and cleaved caspase 7 in Jurkat and KOPT-K1 after the treatment of doxorubicin.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106699-fig6-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6s1sdata2"><label>Figure 6—figure supplement 1—source data 2.</label><caption><title>Western blot raw data shows the expression of caspase 7 and cleaved caspase 7 in Jurkat and KOPT-K1 after the treatment of doxorubicin.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106699-fig6-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106699-fig6-figsupp1-v1.tif"/></fig></fig-group><p>Conversely, the effect of both compounds on the LMO2-negative Jurkat cells was a small increase in caspase 3/7 levels over the time course of the experiment. This increased 2.6-fold (from 16,223 RLU at 4 hr to 43,651 RLU at 30 hr) using Abd-CRBN and 4.5-fold (from 20,309 RLU at 4 hr to 92,683 RLU at 30 hr) using Abd-VHL. Western blotting analysis up to 48 hr of treatment with compounds did not show significant levels of activated, cleaved caspase 3, and only small amounts of activated, cleaved caspase 7 at 48 hr after treatment with Abd-CRBN (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Similarly, Abd-VHL treatment (<xref ref-type="fig" rid="fig6">Figure 6C</xref>) of Jurkat cells did not induce detectable cleaved caspase 3 or 7 in the western blotting analysis. Small amounts of cleaved PARP were detected in the Western blotting analysis for treatment with both Abd compounds. Cells treated with only DMSO in culture medium showed essentially no detectable activated caspase 3/7 during this growth period (<xref ref-type="fig" rid="fig6">Figure 6A</xref>) nor activated, cleaved caspase or PARP (<xref ref-type="fig" rid="fig6">Figure 6B and C</xref>). To corroborate the detection system for cleaved caspase 7, both Jurkat and KOPT-K1 cells were treated with the chemotherapy reagent doxorubicin and analysed by western blotting and luminescence assays (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><sec id="s3-1"><title>LMO2 depletion by antibody biodegraders or PROTACs interferes with T-ALL</title><p>Transcription factors like LMO2 have been considered as hard-to-drug targets because they are involved in protein-protein or protein-DNA interaction and often have large intrinsically disordered regions, as in the case of LMO2 (<xref ref-type="bibr" rid="bib34">Sewell et al., 2014</xref>). Therefore, using intracellular antibodies as inhibitors is a convenient starting point for drug discovery with these IDPs. In this study, we have shown that protein degradation of the LMO2 transcription factor occurs after either a binary interaction of an iDAb-E3 ligase fusion with LMO2 or a ternary interaction through PROTACs. Using an intracellular antibody for study of IDPs offers unique options because of the natural property of antibodies of high discriminating power, they can be easily manipulated by protein engineering (<xref ref-type="bibr" rid="bib44">Winter, 1989</xref>) and can be used for target validation as a step before embarking on small-molecule drug development campaigns.</p><p>The function of LMO2 to regulate cell proliferation has been found involved during tumourigenesis, and the inhibition of LMO2 showed apoptosis induction in breast and colorectal cancer (<xref ref-type="bibr" rid="bib20">Liu et al., 2016</xref>). In acute myeloid leukaemia cells, the LMO2/LDB1 complex has an important role to promote cell growth and proliferation and is required for cell survival (<xref ref-type="bibr" rid="bib22">Lu et al., 2023</xref>). Our data show that the depletion of LMO2 has an effect on growth of T-ALL-expressing LMO2 but that the compounds have no off-target effect on non-expressing LMO2 T-ALL cells. Proteomic analysis (<xref ref-type="fig" rid="fig5">Figure 5</xref>) exploring the pathways associated with LMO2 protein reduction in T-ALL cells supports the conclusion that LMO2 down-regulation has an effect on proteins required for cell division, coupled to down-regulation of components of the ubiquitination machinery, known to coordinate phases and progression of cell division (<xref ref-type="bibr" rid="bib48">Zou and Lin, 2021</xref>). Suppression of ubiquitination reduces proliferation and induces apoptosis, which was observed in treated cells (<xref ref-type="fig" rid="fig6">Figure 6</xref>). Further, several proteins involved in mitosis are reduced upon LMO2 degradation (annotated in <xref ref-type="supplementary-material" rid="fig5sdata3">Figure 5—source data 3</xref>), such as CCNA2 (cyclin A2), which controls G1/S and the G2/M transitions (<xref ref-type="bibr" rid="bib48">Zou and Lin, 2021</xref>), is reduced in the LMO2 PROTAC-treated cells. In relation to ubiquitination itself and protein turnover, it is significant that both UBE2C and UBE2S E2 ubiquitin enzymes are reduced in LMO2-depleted cells. These two E2 enzymes ubiquitinate anaphase-promoting complex/cyclosome required proteasomal loss of cyclin B1 for exiting from mitosis (<xref ref-type="bibr" rid="bib1">Alfieri et al., 2017</xref>). Overall, the data suggest that when LMO2 is depleted from the T-ALL cells, the effect is to block mitosis and apoptosis follows.</p></sec><sec id="s3-2"><title>Collateral turnover of transcription factor partners with LMO2 proteasome degradation</title><p>The LMO2 protein is a transcription factor that operates as a bridging molecule for a multi-protein complex that binds to DNA through bipartite regions comprising a bHLH heterodimer of TAL1 and E47 (binding to E box elements) and a GATA protein (binding to GATA elements) (<xref ref-type="bibr" rid="bib40">Wadman et al., 1997</xref>). While LIM-only proteins have two LIM domains, each with two LIM zinc-binding fingers, these proteins do not interact directly with DNA. The LMO2 protein complex is required for function within T-ALL, and forced expression of LMO2 and TAL1 in transgenic mouse models demonstrated this leukaemogenesis cooperativity (<xref ref-type="bibr" rid="bib17">Larson et al., 1996</xref>). However, in the experimental system described here, we have demonstrated the effects on cell growth by treating T cells with the LMO2 PROTACs, and both TAL1 and E47 were rapidly and simultaneously degraded with LMO2 (<xref ref-type="fig" rid="fig1">Figures 1</xref> and <xref ref-type="fig" rid="fig3">3</xref>). Since there is a close association of the two bHLH with LMO2 proteins within the protein complex, lysines in these two proteins that lie close to the PROTAC-binding site (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>) could also undergo ubiquitination. Such an effect was described as bystander ubiquitination (<xref ref-type="bibr" rid="bib9">Bond and Crews, 2021</xref>). Alternatively, degradation of LMO2 could destabilise the whole complex, in a natural process of transcription complex regulation, causing degradation of TAL1 and E47, as previously reported with PROTACs targeting the BAF chromatin remodelling complex (<xref ref-type="bibr" rid="bib16">Farnaby et al., 2019</xref>). In addition, the half-lives of proteins in the LMO2 protein complex were examined using cycloheximide to block protein synthesis. The result showed that TAL1 and E47 have a short half-life (10 min and 1 hr, respectively, in this assay, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>) and LMO2 protein has a half-life of around 6 hr (<xref ref-type="bibr" rid="bib18">Layer et al., 2020</xref>).</p><p>We could not find evidence of differential loss of other members of the complex (LDB1 and GATA) or LYL1, which is a different bHLH protein implicated in T-ALL. This may be because bystander ubiquitination could not occur due to the interaction surfaces of these proteins in relation to the PROTAC docking sites. Alternatively, the disparity in the degradation of LMO2, TAL1, and E47 compared with LDB1 and GATA proteins may be attributed to different pool sizes for LMO2-bound and free components of the transcription complex. The loss of TAL1 and E47 bHLH proteins along with LMO2 in the degradation cascade is, however, a complementary effect that enhances the effectiveness of anti-LMO2 PROTAC compounds.</p></sec><sec id="s3-3"><title>A strategy for drug discovery against IDPs</title><p>Either of the two compounds described here may be developed for specifically treating T-ALL expressing LMO2. Furthermore, our data also illustrate a strategy for drug discovery for IDPs, estimating that up to 30% cellular proteins have large intrinsically disordered regions (<xref ref-type="bibr" rid="bib13">Deiana et al., 2019</xref>), for instance, transcription factors. Starting with a domain antibody that had been used for LMO2 target validation (<xref ref-type="bibr" rid="bib37">Tanaka et al., 2011</xref>), compound surrogates were discovered using the antibody as a screening tool (<xref ref-type="bibr" rid="bib5">Bery et al., 2021</xref>) and the compounds developed using medicinal chemistry. This is a general approach for hard-to-drug, disordered proteins such as transcription factors.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-LMO2 (Goat polyclonal)</td><td align="left" valign="bottom"> R&amp;D Systems</td><td align="left" valign="bottom">Cat#AF2726<break/> RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2249968">AB_2249968</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-pan-RAS (Mouse monoclonal)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# OP40-100UG<break/> RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_10683383">AB_10683383</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-CRBN (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat# 71810,<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2799810">AB_2799810</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-VHL (Rabbit monoclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# PA5-27322, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2544798">AB_2544798</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-PARP (Rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat# 9542, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2160739">AB_2160739</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-TAL1 (Rabbit polyclonal)</td><td align="left" valign="bottom">A gift from Prof. Richard Bear (Columbia University)</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">WB (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-E2A (E47)<break/>(Rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat# 4865, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_10560512">AB_10560512</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-GATA-3 (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat# 5852, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_10835690">AB_10835690</ext-link></td><td align="left" valign="bottom">WB (1:5000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-LYL1 (Rabbit polyclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# PA5-68772, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2691101">AB_2691101</ext-link></td><td align="left" valign="bottom">WB (1:5000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-LDB1 (Rabbit polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab96799, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_10679400">AB_10679400</ext-link></td><td align="left" valign="bottom">WB (1:5000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-caspase-3<break/>(Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat# 9665, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2069872">AB_2069872</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-cleaved caspase-3 (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat# 9664, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2070042">AB_2070042</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-caspase-7<break/>(Rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat# 9492, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2228313">AB_2228313</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-cleaved caspase-7 (Rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom"> Cat# 9491, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2068144">AB_2068144</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-FLAG M2<break/>(Mouse monoclonal)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# F1804, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_262044">AB_262044</ext-link></td><td align="left" valign="bottom">WB (1:10,000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-β-Actin (Mouse antibody)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# A5441, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_476744">AB_476744</ext-link></td><td align="left" valign="bottom">WB (1:10,000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-cyclophilin-B (Rabbit polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab178397, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2924975">AB_2924975</ext-link></td><td align="left" valign="bottom">WB (1:10,000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-α-Tubulin<break/>(Rabbit polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab4074, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2288001">AB_2288001</ext-link></td><td align="left" valign="bottom">WB (1:10,000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-goat IgG HRP-linked antibody<break/>(Rabbit polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab6741, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_955424">AB_955424</ext-link></td><td align="left" valign="bottom">WB (1:10,000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-rabbit IgG HRP-linked antibody</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat# 7071, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2099234">AB_2099234</ext-link></td><td align="left" valign="bottom">WB (1:10,000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse IgG HRP-linked antibody<break/>(Horse polyclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat# 7076, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_330924">AB_330924</ext-link></td><td align="left" valign="bottom">WB (1:10,000)</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">CellTiter-Glo</td><td align="left" valign="bottom"> Promega</td><td align="left" valign="bottom">Cat# G8090</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Caspase-Glo 3/7</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">Cat# G7570</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Pierce BCA Protein assay kit</td><td align="left" valign="bottom">Thermo Scientific</td><td align="left" valign="bottom">Cat# 23225</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">von Hippel-Lindau (VHL) Ligand 1</td><td align="left" valign="bottom">Cayman Chemical</td><td align="left" valign="bottom">Cat# 21591</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Cereblon (CRBN)</td><td align="left" valign="bottom">A gift from Dr. Habib Bouguenina</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Thalidomide</td><td align="left" valign="bottom">A gift from Dr. Habib Bouguenina</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Lenalidomide</td><td align="left" valign="bottom">A gift from Dr. Habib Bouguenina</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Epoxomicin</td><td align="left" valign="bottom">A gift from Dr. Habib Bouguenina</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">MLN4924</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat# 6499</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GraphPad Prism</td><td align="left" valign="bottom">GraphPad Prism</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_002798">SCR_002798</ext-link></td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Molecular cloning</title><p>The iDAb LMO2-E3 ligase fusions were generated by polymerase chain reaction (PCR) using Phusion High-Fidelity PCR kit (NEB). pEF-VH576-L10-FLAG-CRBN-mb was used as a template to generate VH576-L10-FLAG-CRBN; pEF-FLAG-CRBN-L5-VH576-myc was used as a template to generate FLAG-CRBN-L5-VH576; pEF-VHL-L5-FLAG-VH576-mb was used as a template to generate VHL-L5-FLAG-VH576; pEF-NtFarn-FLAG-VH576-L10-VHL was used as a template to generate FLAG-VH576-L10-VHL; pEF-UBOX-L5-FLAG-VH576-mb was used as a template to generate UBOX-L5-FLAG-VH576; pEF-NtFarn-FLAG-VH576-L5-UBOX was used as a template to generate FLAG-VH576-L5-UBOX. All the PCR templates were previously described (<xref ref-type="bibr" rid="bib5">Bery et al., 2021</xref>). PCR products were cloned into pEF-BOS plasmid and sequenced to confirm insert with the vector.</p><p>Generation of LMO2, MAX, RHOBWT-FL, KRASWT-FL, GFP<sup>2</sup>, ISL-1, and Zn268 was by PCR using Phusion High-Fidelity PCR kit (NEB) and cloned into pEF-BOS-Rluc8 plasmid to produce pEF-LMO2-Rluc8, pEF-MAX-Rluc8, pEF-Rluc8-RHOBWT-FL, pEF-Rluc8-KRASWT-FL, pEF-GFP<sup>2</sup>-Rluc8, pEF-ISL-1-Rluc8, and pEF-Zn268-Rluc8 (<xref ref-type="bibr" rid="bib5">Bery et al., 2021</xref>; <xref ref-type="bibr" rid="bib6">Bery and Rabbitts, 2022</xref>).</p></sec><sec id="s4-2"><title>Cell culture</title><p>Human T-ALL cell lines – KOPT-K1, Jurkat, MOLT-3, ALL-SIL, DND-41, PF382, SUPT-1, RPMI8402, and P12-Ichikawa – were cultured in RPMI-1640 medium (Gibco) supplemented with 10% foetal bovine serum (FBS) (Pan-Biotech). HEK293T cell line was cultured in DMEM (Gibco) supplemented with 10% FBS. Cells were grown at 37°C in a humidified incubator with 5% CO<sub>2</sub> and were regularly performed mycoplasma tests using a MycoAlert Mycoplasma Detection Kit (Lonza). Cells that were mycoplasma-free were used for experiments.</p></sec><sec id="s4-3"><title>Transient transfection</title><p>HEK293T cells were seeded on a six-well plate at 3×10<sup>5</sup> cells/well and incubated at 37°C with 5% CO<sub>2</sub> until 70–80% confluence determined visually. After 24 hr, cells were transfected with Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s instructions. An iDAb LMO2-E3 ligase plasmid (ranging from 0 to 1.0 μg) was mixed with 1 μg pEF-BOS-LMO2 expression vector (<xref ref-type="bibr" rid="bib24">Osada et al., 1995</xref>) and diluted in 150 µl Opti-MEM reduced serum medium (Gibco). 10 μl Lipofectamine 2000 was diluted in 150 µl Opti-MEM reduced serum medium. The diluted DNA was added to diluted Lipofectamine 2000 and incubated for 15 min at room temperature. After the incubation, the mixture was added to the HEK293T cells. After 24 hr of transfection, the transfected cells were detached from the plate using trypsin-EDTA (0.05%), Phenol Red (Gibco) and incubated at 37°C for 2 min. Two volumes of pre-warmed complete media were added to inactivate trypsin, and dispersal of the medium, by pipetting over the cell layer surface, was used to recover &gt;95% of cells. Cell pellets were collected by centrifugation at 100×<italic>g</italic> for 5 min at room temperature.</p></sec><sec id="s4-4"><title>Luciferase reporter assay</title><p>HEK293T cells were transiently transfected with 500 ng reporter vectors (pEF-LMO2-Rluc8, pEF-MAX-Rluc8, pEF-RHOBWT-FL-Rluc8, pEF-KRASWT-FL-Rluc8, pEF-GFP<sup>2</sup>-Rluc8, pEF-ISL-1-Rluc8, or pEF-Zn268-Rluc8). After 24 hr, the transfected cells were re-seeded in white opaque 96-well plate at 5×10<sup>4</sup> cells/well and incubated at 37°C for 4 hr prior to the compound addition. The treated cells were incubated at 37°C for 24 hr, after which 10 μl of 250 μM luciferase substrate (Coelenterazine 400a) (Cayman Chemical) were added per well to get 10 μM at final concentration. The luminescence signal was measured at 400–700 nm wavelength filter luminescence using PHERAstar FSX (BMG Labtech).</p></sec><sec id="s4-5"><title>Lentiviral cell lines</title><p>The lentiviral transfer vector plasmid TLCV2-VH576-L10-FLAG-CRBN was constructed with TLCV2 (<xref ref-type="bibr" rid="bib2">Barger et al., 2019</xref>). The pMA-VH576-L10-FLAG-CRBN was synthesised from GeneArt (Thermo Fisher). The insert was removed from the pMA vector by digesting with AgeI and NheI, then cloned into TLCV2 vector between Age/NheI sites to produce a TLCV2-VH576-L10-FLAG-CRBN plasmid.</p><p>Lentiviral particles were produced by transient co-transfection of lentiviral transfer vector plasmid and the packaging plasmids (pRSV-Rev, pMDLg/pRRE, and pMD2-VSV-G) in HEK293T cells using Lipofectamine 2000. After 48 hr transfection, debris was removed by spinning at 300×<italic>g</italic> for 5 min at 4°C, followed by filtration of the supernatants through 0.45 μm filter to remove viral aggregates. The filtered lentiviral supernatants were centrifuged at 15,000×<italic>g</italic> for 24 hr at 4°C. Virus pellets were resuspended in completed media and stored at –80°C in cryotubes. The lentiviral particles were titrated by serial dilution (3× dilution) in complete media. After 48 hr post-transduction, cells were harvested and analysed by flow cytometry for the viral GFP reporter expression and the viral titres calculated.</p></sec><sec id="s4-6"><title>T cell transduction</title><p>KOPT-K1 and Jurkat cells were infected by using TransDux MAX virus transduction reagent and followed the spinoculation method (SBI, System Bioscience). For the spinoculation, KOPT-K1 and Jurkat were seeded in a 24-well plate at 5×10<sup>5</sup> cells/well and resuspended with 400 μl complete RPMI media plus 100 μl MAX Enhancer, 2 μl TransDux, and 4 μl 1 M HEPES pH 7.0 buffer. Virus suspensions were added to cells at a multiplicity of infection of 3, and the plate was centrifuged at 1500×<italic>g</italic> at 32°C for 2 hr. After spinoculation, the presence of the cells was verified at the bottom of the wells, and 400 μl complete medium was added to each well. Cells were resuspended by pipetting. The cell suspensions were transferred to 1.5 ml sterile tubes and centrifuged at 1,500×<italic>g</italic> for 5 min at room temperature. The supernatant was discarded to remove the transduction reagent, and cells were resuspended in 400 μl fresh complete media and transferred to a new 24-well plate. The infected cells were incubated at 37°C, 5% CO<sub>2</sub> incubator for 48 hr. The doxycycline was added to induce the biodegrader expression before analysis by flow cytometry and western blotting.</p></sec><sec id="s4-7"><title>Western blotting</title><p>Cells were washed with PBS before lysis with RIPA buffer (Sigma-Aldrich) (50 mM Tris-HCl, pH 8.0, 150 mM sodium chloride, 1.0% Igepal CA-630 [NP-40], 0.5% sodium deoxycholate [SDC], and 0.1% sodium dodecyl sulphate) supplemented with Pierce protease inhibitor tablets, EDTA-free (Thermo Fisher). Cells were lysed on ice and vortexed every 5 min for 30 min, then centrifuged at 10,000×<italic>g</italic>, 10 min at 4°C. Protein concentrations were quantified using Pierce BCA Protein assay kit (Thermo Fisher) with the BCA standard curve range from 0 to 2 mg/ml. Equal amounts of protein samples were separated on 10% or 15% SDS-PAGE and subsequently transferred to polyvinylidene fluoride membrane (Amersham, Cytiva) by wet blotting method. The membrane was blocked with 10% non-fat milk (Sigma-Aldrich) in PBST (PBS with 0.1% Tween20 [Sigma-Aldrich]) before incubation with primary antibodies overnight at 4°C on a roller. After the incubation, the membrane was washed with PBST for 5 min and the washing step was repeated five times. The washed membrane was incubated with horseradish peroxidase-conjugated secondary antibodies at room temperature for 1 hr on a roller, then washed with PBST for 5 minutes, repeating the washing step five times. The membrane was incubated with Clarity western blotting substrate (Bio-Rad) for 1 min before exposure to a ChemiDoc Imager (Bio-Rad). For quantification, densitometry analysis of protein expression was analysed using Image Lab software.</p></sec><sec id="s4-8"><title>Reverse transcription-PCR</title><p>The expression of <italic>LMO1</italic> and <italic>LMO2</italic> was verified using RT-PCR method using the primers shown in <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>. 1×10<sup>7</sup> cells were harvested and lysed by using 0.5% NP40 lysis buffer (Thermo Scientific). Total cellular RNA was extracted from the supernatant by using water-saturated phenol pH 6.6 (Invitrogen), 2 M NaAc pH 5.0 was added to 300 mM, and 100% ethanol to 70% to precipitate RNA at –20°C for 2 hr. The pellet was washed with 70% aqueous ethanol and dried at room temperature. The RNA precipitate was dissolved in 10 mM Tris pH 7.5. The final RNA concentration was measured using a NanoDrop spectrophotometer (Thermo Scientific). Two μg of RNA was used for first-strand cDNA synthesis with 100 pmoles oligo(dT)<sub>12-18</sub> primer (Invitrogen) and 20 units SuperScript II Reverse Transcriptase (Invitrogen). Primers for LMO1 were forward 5’-<named-content content-type="sequence">GATCCAGCCCAAAGGGAAGCAG</named-content>-3’, reverse 5’-<named-content content-type="sequence">GATAAAGGTGCCATTG</named-content> AGCTG-3’. Primers for LMO2 were forward 5’-<named-content content-type="sequence">GATTCCTCGGCCATCGAAAGG</named-content>-3’, reverse 5’-<named-content content-type="sequence">GATGTTTGTAGTAGAGGCGCCG</named-content>-3’. Primers for KRAS were forward 5’-<named-content content-type="sequence">GATATGACTGAATATAAACTTGTGGTAG</named-content>-3’, reverse 5’-<named-content content-type="sequence">GATGGCAAATACACAAAGA</named-content> AAGC-3’. PCR was performed by using DNA Engine Tetrad Thermal Cycler (Bio-Rad). The PCR conditions were 98°C 1 min 1 cycle for initial denaturation, and 30 cycles of 98°C 10 s for denaturation, 65°C 15 s for annealing, 72°C 30 s per 1 kb for extension, then 72°C 10 min for final extension. The PCR products were resolved on 1.0% agarose gel, visualised by SYBR Safe staining, and quantified using ChemiDoc Imager (Bio-Rad).</p></sec><sec id="s4-9"><title>Genomic PCR</title><p>The presence of the chromosomal translocation t(11;14)(p13;q11) in KOPT-K1 cells (<xref ref-type="bibr" rid="bib14">Dong et al., 1995</xref>) was confirmed using genomic PCR. The derived genomic translocation sequence is shown in <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>. Total DNA was extracted from 1×10<sup>6</sup> KOPT-K1 cells by using DNeasy Blood&amp;Tissue Kit (QIAGEN) according to the manufacturer’s instruction. The final DNA concentration was measured using a NanoDrop spectrophotometer (Thermo Scientific). One hundred ng of DNA template was used to generate PCR using Phusion High-Fidelity PCR Kit (NEB). PCR was performed by using DNA Engine Tetrad Thermal Cycler (Bio-Rad). The forward and reverse primers used to confirm the chromosomal translocation in KOPT-K1 were forward two 5’-GATGAAT <named-content content-type="sequence">TCGAAGCTACTGCAGCCATC</named-content>-3’, forward three 5’-<named-content content-type="sequence">GATGAATTCATGCTATGAGGTA</named-content> GGTATG-3’, and J delta reverse 5’-<named-content content-type="sequence">GATGGATCCGGTTCCACAGTCACTCGGGTTCC</named-content>-3’. The PCR condition was 98°C 1 min 1 cycle for initial denaturation, followed by 98°C 10 s for denaturation, 65°C 15 s for annealing, 72°C 15 s for extension for 30 cycles, then 72°C 10 min for final extension. The PCR products were resolved on 1% agarose gel, visualised by SYBR Safe staining, and quantified using ChemiDoc Imager (Bio-Rad).</p></sec><sec id="s4-10"><title>Chemistry: synthesis, purification, and quality control</title><sec id="s4-10-1"><title>Synthesis of Abd-CRBN</title><sec id="s4-10-1-1"><title>Ethyl 2-(4-(3-methoxybenzyl)piperazin-1-yl)oxazole-4-carboxylate</title><fig id="C1" position="anchor"><label>Chemical structure 1.</label><caption><title>ethyl 2-(4-(3-methoxybenzyl)piperazin-1-yl)oxazole-4-carboxylate.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106699-chem1-v1.tif"/></fig><p>1-(3-Methoxybenzyl)piperazine (150 mg, 0.728 mmol, 1.2 eq.) was dissolved in 1,4-dioxane/<italic>N</italic>,<italic>N</italic>-diisopropylethylamine (4:1, 5 ml) before addition of ethyl 2-chlorooxazole-4-carboxylate (116 mg, 0.661 mmol, 1.0 eq.). The solution was stirred at 60°C for 48 hr, cooled down to room temperature, diluted with EtOAc (20 ml) and washed with H<sub>2</sub>O/brine (1:1, 20 ml). The organic phase was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated in vacuo. The crude material was then purified on silica gel (4% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) to afford the title compound as a yellow oil (163 mg, 71%), after purification on silica gel (4% MeOH in CH<sub>2</sub>Cl<sub>2</sub>).</p></sec><sec id="s4-10-1-2"><title>Ethyl 2-(4-(3-methoxybenzyl)piperazin-1-yl)oxazole-4-carboxylate</title><fig id="C2" position="anchor"><label>Chemical structure 2.</label><caption><title>ethyl 2-(4-(3-methoxybenzyl)piperazin-1-yl)oxazole-4-carboxylate.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106699-chem2-v1.tif"/></fig><p>Ethyl 2-(4-(3-methoxybenzyl)piperazin-1-yl)oxazole-4-carboxylate (200 mg, 0.580 mmol, 1.0 eq.) was dissolved in THF/MeOH (4:1) before addition of NaOH (1 M aq.) until pH&gt;8. The resulting reaction was stirred for 16 hr at room temperature and then acidified with HCl (1 M aq.) until pH&lt;5. The solution was concentrated in vacuo and the obtained carboxylic acid (184 mg, quant.) was used directly in the next step.</p></sec><sec id="s4-10-1-3"><title>Ethyl 4-(2-(4-(3-methoxybenzyl)piperazin-1-yl)oxazole-4-carboxamido)benzoate</title><fig id="C3" position="anchor"><label>Chemical structure 3.</label><caption><title>ethyl 4-(2-(4-(3-methoxybenzyl)piperazin-1-yl)oxazole-4-carboxamido)benzoate.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106699-chem3-v1.tif"/></fig><p>2-(4-(3-Methoxybenzyl)piperazin-1-yl)thiazole-4-carboxylic acid (184 mg, 0.580 mmol, 1.0 eq.) was dissolved in DMF (4 ml) before sequential addition of <italic>N</italic>,<italic>N</italic>-diisopropylethylamine (303 µl, 1.74 mmol, 3.0 eq.), benzocaine (115 mg, 0.696 mmol, 1.2 eq.) and HATU (309 mg, 0.812 mmol, 1.4 eq.). The resulting solution was stirred for 18 hr, diluted with EtOAc (10 ml), and washed with brine/water (1:1, 3×50 ml). The organic phase was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated in vacuo. The title product was obtained as a colourless oil that solidified on standing (247 mg, 92%), after purification on silica gel (4% MeOH in CH<sub>2</sub>Cl<sub>2</sub>).</p></sec><sec id="s4-10-1-4"><title>4-(2-(4-(3-Methoxybenzyl)piperazin-1-yl)oxazole-4-carboxamido)benzoic acid</title><fig id="C4" position="anchor"><label>Chemical structure 4.</label><caption><title>4-(2-(4-(3-methoxybenzyl)piperazin-1-yl)oxazole-4-carboxamido)benzoic acid.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106699-chem4-v1.tif"/></fig><p>Ethyl 4-(2-(4-(3-methoxybenzyl)piperazin-1-yl)oxazole-4-carboxamido)benzoate (120 mg, 0.252 mmol, 1.0 eq.) was dissolved in THF/MeOH (4:1) before addition of NaOH (1 M aq.) until pH&gt;8. The resulting reaction was stirred for 16 hr at room temperature and then acidified with HCl (1 M aq.) until pH&lt;5. The solution was concentrated in vacuo and the obtained carboxylic acid (114 mg, quant.) was used directly in the next step.</p></sec><sec id="s4-10-1-5"><title><italic>N</italic>-(4-((6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)hexyl)carbamoyl)phenyl)-2-(4-(3-methoxybenzyl)piperazin-1-yl)oxazole-4-carboxamide</title><fig id="C5" position="anchor"><label>Chemical structure 5.</label><caption><title>N-(4-((6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)hexyl)carbamoyl)phenyl)-2-(4-(3-methoxybenzyl)piperazin-1-yl)oxazole-4- carboxamide.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106699-chem5-v1.tif"/></fig><p>4-(2-(4-(3-Methoxybenzyl)piperazin-1-yl)oxazole-4-carboxamido)benzoic (65 mg, 0.150 mmol, 1.2 eq.) was dissolved in DMF (1 ml) before sequential addition of <italic>N</italic>,<italic>N</italic>-diisopropylethylamine (66 µl, 0.381 mmol, 3.0 eq.), 4-((6-aminohexyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (47 mg, 0.127 mmol, 1.0 eq.) and HATU (80 mg, 0.210 mmol, 1.4 eq.). The resulting solution was stirred for 18 hr, diluted with EtOAc (10 ml) and washed with brine/water (1:1, 3×50 ml). The organic phase was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated in vacuo. The title product was obtained as a colourless oil (89 mg, 89%), after purification on silica gel (10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>).</p></sec></sec></sec><sec id="s4-11"><title>Synthesis of Abd-VHL</title><p><italic>tert</italic>-Butyl 2-(2-(2-aminoethoxy)ethoxy)acetate was prepared following literature precedent.</p><fig id="C6" position="anchor"><label>Chemical structure 6.</label><caption><title>Synthesis of Abd-VHL.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106699-chem6-v1.tif"/></fig><sec id="s4-11-1"><title><italic>tert</italic>-Butyl 2-(2-(2-(4-(2-(4-(3-methoxybenzyl)piperazin-1-yl)thiazole-4-carboxamido)benzamido)ethoxy)ethoxy)acetate</title><fig id="C7" position="anchor"><label>Chemical structure 7.</label><caption><title>tert-butyl 2-(2-(2-(4-(2-(4-(3-methoxybenzyl)piperazin-1-yl)thiazole-4-carboxamido) benzamido)ethoxy)ethoxy)acetate.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106699-chem7-v1.tif"/></fig><p>4-(2-(4-(3-Methoxybenzyl)piperazin-1-yl)thiazole-4-carboxamido)benzoic (36 mg, 0.080 mmol, 1.0 eq.) was dissolved in DMF (1 ml) before sequential addition of <italic>N</italic>,<italic>N</italic>-diisopropylethylamine (42 µl, 0.240 mmol, 3.0 eq.), <italic>tert</italic>-butyl 2-(2-(2-aminoethoxy)ethoxy)acetate (20 mg, 0.086 mmol, 1.2 eq.) and HATU (43 mg, 0.112 mmol, 1.4 eq.). The resulting solution was stirred for 18 hr, diluted with EtOAc (10 ml), and washed with brine/water (1:1, 3×50 ml). The organic phase was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated in vacuo. The title product was obtained as a colourless oil (30 mg, 57%), after purification on silica gel (10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>).</p></sec><sec id="s4-11-2"><title>2-(2-(2-(4-(2-(4-(3-Methoxybenzyl)piperazin-1-yl)thiazole-4 carboxamido)benzamido) ethoxy)ethoxy) acetic acid</title><fig id="C8" position="anchor"><label>Chemical structure 8.</label><caption><title>2-(2-(2-(4-(2-(4-(3-methoxybenzyl)piperazin-1-yl)thiazole-4 carboxamido)benzamido) ethoxy)ethoxy) acetic acid.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106699-chem8-v1.tif"/></fig><p><italic>tert</italic>-Butyl 2-(2-(2-(4-(2-(4-(3-methoxybenzyl)piperazin-1-yl)thiazole-4-carboxamido)benzamido)ethoxy)ethoxy)acetate (30 mg, 0.046 mmol, 1.0 eq.) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (1 ml) before addition of TFA (10 µl) in one portion. The reaction was stirred for 16 hr at room temperature, concentrated in vacuo, and the title product was obtained as a yellow oil (27 mg, quant.) and used directly in the next step.</p></sec></sec><sec id="s4-12"><title>VHL ligand</title><p>The VHL ligand ((2<italic>S</italic>,4<italic>R</italic>)-1-((<italic>R</italic>)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-<italic>N</italic>-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide) was prepared following literature precedent with a small modification; the first two steps were replaced by a Suzuki reaction. The final product was columned before use (not carried out in the literature).</p><fig id="C9" position="anchor"><label>Chemical structure 9.</label><caption><title>VHL ligand.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106699-chem9-v1.tif"/></fig><sec id="s4-12-1"><title><italic>N</italic>-(4-((2-(2-(2-(((R)-1-((2<italic>S</italic>,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl) pyrrolidine-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)ethoxy)ethyl)carbamoyl)phenyl)-2-(4-(3-methoxybenzyl)piperazin-1-yl)thiazole-4-carboxamide</title><fig id="C10" position="anchor"><label>Chemical structure 10.</label><caption><title>N-(4-((2-(2-(2-(((R)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl) pyrrolidine-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2 oxoethoxy)ethoxy)ethyl) carbamoyl)phenyl)-2-(4-(3-methoxybenzyl)piperazin-1-yl)thiazole-4-carboxamide.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106699-chem10-v1.tif"/></fig><p>2-(2-(2-(4-(2-(4-(3-Methoxybenzyl)piperazin-1-yl)thiazole-4 carboxamido)benzamido) ethoxy)ethoxy)acetic acid (20 mg, 0.033 mmol, 1.0 eq.) was dissolved in DMF (1 ml) before sequential addition of <italic>N</italic>,<italic>N</italic>-diisopropylethylamine (17 µl, 0.100 mmol, 3.0 eq.), 2<italic>S</italic>,4(<italic>R</italic>)-1-((<italic>R</italic>)–2-amino-3,3-dimethylbutanoyl)-4-hydroxy-<italic>N</italic>-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (17 mg, 0.040 mmol, 1.2 eq.) and HATU (18 mg, 0.046 mmol, 1.4 eq.). The resulting solution was stirred for 18 hr, diluted with EtOAc (10 ml) and washed with brine/water (1:1, 3×50 ml). The organic phase was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated in vacuo. The title product was obtained as a colourless oil (9 mg, 27%), after purification on silica gel (18% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), followed by two successive preparative TLC (15% MeOH in CH<sub>2</sub>Cl<sub>2</sub> with double elution).</p></sec></sec><sec id="s4-13"><title>Cell assays with Abd-CRBN, Abd-VHL, and inhibitors</title><p>Assays for the LMO2 PROTAC compounds Abd-CRBN and Abd-VHL were carried out with compounds synthesised by contract with O2H Discovery. All compounds (Abd compounds and epoxomicin, thalidomide, VHL, and MLN4924) were dissolved in 100% DMSO at 10 mM and stored in small aliquots at –20°C. The stability of the compounds was evaluated before using for experiments by using LC-MS method using a Xevo TQ Mass Spectrometer instrument.</p></sec><sec id="s4-14"><title>Cell viability assays</title><p>The number of viable cells was measured by staining cells with 0.4% Trypan Blue solution (Invitrogen) and counting with Countess Automated Cell Counter (Invitrogen). For inhibition studies, KOPT-K1 cells were seeded in a six-well plate at 5×10<sup>5</sup> cells/well. After the incubation at 37°C in a humidified incubator with 5% CO<sub>2</sub> for 24 hr, cells were pre-treated with inhibitor compounds (epoxomicin, thalidomide, or lenalidomide) or Neddylation inhibitor (MLN4924) for 2 hr or proteasome inhibitor (epoxomicin) for 24 hr prior to the treatment of Abd compounds for 24 hr. For apoptosis studies, KOPT-K1 cells were seeded in a six-well plate at 5×10<sup>5</sup> cells/well. After the incubation at 37°C in a humidified incubator with 5% CO<sub>2</sub> for 24 hr, cells were treated with Abd-CRBN or Abd-VHL for 24 or 48 hr.</p><p>Cell viability was also assessed by CellTiter-Glo (Promega) according to the manufacturer’s instructions. Cells were seeded in triplicate in white 96-well plates (PerkinElmer) at 1×10<sup>4</sup> cells/well. After the treatment with compounds, an equal amount of CellTiter-Glo reagent was added to each well and incubated at room temperature for 10 min before the luminescence signal measurement using PHERAstar FSX (BMG Labtech).</p></sec><sec id="s4-15"><title>Dose response and EC<sub>50</sub> determination</title><p>KOPT-K1, Jurkat, and MOLT-3 cells were seeded in white 96-well plate at 1×10<sup>4</sup> cells/well and incubated at 37°C in a humidified incubator with 5% CO<sub>2</sub>. After 24 hr incubation, cells were treated with 5, 10, 15, 20, or 25 μM of Abd-CRBN or Abd-VHL for 24 hr. The viable cells were measured using the CellTiter-Glo assay. The EC<sub>50</sub> was calculated using Prism 9 GraphPad Software. For dose response by western blotting analysis, KOPT-K1 and Jurkat cells were seeded in six-well plates at 5×10<sup>5</sup> cells/well and the incubation at 37°C in a humidified incubator with 5% CO<sub>2</sub> for 24 hr. Then, cells were treated with Abd-CRBN or Abd-VHL compounds at concentrations of 5, 10, or 20 µM for 2, 6, or 24 hr.</p></sec><sec id="s4-16"><title>Caspase3/7 activity assay</title><p><ext-link ext-link-type="uri" xlink:href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/caspase">Caspase</ext-link> activities were measured using Caspase-Glo 3/7 (Promega) according to the manufacturer’s instruction. Cells were seeded in triplicate in white 96-well plates (PerkinElmer) at 1×10<sup>4</sup> cells/well. After the treatment with Abd-CRBN or Abd-VHL compounds for 24 hr, an equal amount of CellTiter-Glo reagent was added to each well and mixed using a plate shaker at 300 rpm for 30 s, incubated the plate at room temperature for 1 hr before the luminescence signal measurement using PHERAstar FSX (BMG Labtech).</p></sec><sec id="s4-17"><title>Proteomic analysis by mass spectrometry</title><p>Samples were prepared using the SimPLIT workflow previously described (<xref ref-type="bibr" rid="bib35">Sialana et al., 2022</xref>) with minor modifications. Cell pellets were lysed in a buffer containing 0.1 M TEAB, 1% SDC, 10% isopropanol, 50 mM NaCl, 5 mM TCEP, 10 mM IAA, nuclease, and protease/phosphatase inhibitors. After 5 min of bath sonication and 45 min at room temperature, protein concentration was measured by Bradford assay. For digestion, 15 µg protein aliquots were treated with trypsin and incubated at 37°C for 2 hr, then overnight at room temperature. Digested samples were acidified, spun, desalted, and labelled with TMTpro-18plex. Labelled samples were combined, acidified, centrifuged to remove SDC, and dried.</p><p>Offline peptide fractionation was based on high pH Reverse Phase (RP) chromatography using the Waters XBridge C18 column (2.1×150 mm<sup>2</sup>, 3.5 μm) on a Dionex Ultimate 3000 HPLC as previously described (<xref ref-type="bibr" rid="bib38">Thomas et al., 2024</xref>) with minor modifications. Retention time-based fractions are collected and pooled into 24 samples for LC-MS analysis.</p><p>Samples were analysed on a Dionex UltiMate 3000 UHPLC with an Orbitrap Ascend Tribrid mass spectrometer and a PepMap C18 capillary column, as previously described (<xref ref-type="bibr" rid="bib38">Thomas et al., 2024</xref>). A 120 min gradient separation was applied. Data acquisition used TMT-SPS-MS3 with real-time database search, targeting precursors between 400 and 1600 m/z, and employing RTS spectral identification of MS2 fragments to trigger SPS-MS3 scans.</p><p>Targeted proteomics analysis by mass spectrometry was further conducted on the fractions containing LMO1 and LMO2 peptides detected in the global proteomics analysis to improve sensitivity. Precursors (593.01, 582.34, 693.68, 745.72, 888.52, and 921.39 m/z) were selected in the quadrupole with an isolation width of 0.7 m/z and fragmented with HCD using 36% collision energy. MS2 spectra were recorded in profile mode in Orbitrap at 45,000 resolutions using a 20-scan mode for the isolation list and an AGC setting of 5×10<sup>5</sup>.</p><p>Mass spectra were analysed using SEQUEST-HT and COMET in Proteome Discoverer 3.0 for protein identification and quantification. Parameters included a 20 ppm precursor mass tolerance, 0.5 Da for TMT-MS3, and 0.02 Da for targeted MS2. Searches targeted fully tryptic peptides with up to 2 mis-cleavages, with TMTpro and carbamidomethylation as static modifications, and methionine oxidation and asparagine/glutamine deamidation as variable. Peptide confidence was estimated with Percolator, FDR set at 0.01, and validated by q value and decoy database search.</p><sec id="s4-17-1"><title>Proteomics data normalisation, analysis, and visualisation</title><p>Each TMT column was normalised by dividing the protein abundance values by the median of each value per column. The normalised data were used to calculate log<sub>2</sub> ratios of treated vs DMSO for all cell lines. GSEA (<xref ref-type="bibr" rid="bib36">Subramanian et al., 2005</xref>) was conducted to evaluate the biological effects of 2294 treatment by analysing log<sub>2</sub> ratios of protein abundance from global proteomics data. The proteins were ranked based on log<sub>2</sub> ratios, indicating up-regulation or down-regulation in 2294-treated samples compared to DMSO controls. Significant GSEA enrichment scores were calculated using the annotation terms using KEGG and GO annotation terms, applying a p-value threshold of &lt;0.05 with Benjamini-Hochberg adjustment. Significant terms were visualised using ridge plots and a heatmap summarising the top 10 terms based on the adjusted p-value.</p></sec></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>Co-founder and share-holder in Kodiform Therapeutics</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Supervision, Funding acquisition, Investigation</p></fn><fn fn-type="con" id="con4"><p>Investigation</p></fn><fn fn-type="con" id="con5"><p>Investigation</p></fn><fn fn-type="con" id="con6"><p>Methodology</p></fn><fn fn-type="con" id="con7"><p>Investigation</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Supervision, Funding acquisition, Writing – original draft, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-106699-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files.</p></sec><ack id="ack"><title>Acknowledgements</title><p>This work was financed by grants from Blood Cancer UK (BCUK 12051 and 19013), CR-UK (Project Development Award), and by ICR Core. We wish to thank Prof. Marc Mansour for providing T-ALL cell lines (P12-Ichikawa, MOLT-4, PF-382, DND-41, and ALL-SIL) and very grateful to Teresa Palomero, Foon Wu-Baer, and Richard Baer for LOUCY, SUP-TI, and RPMI8402 cells. We also thank various ICR colleagues for generously providing reagents, the ICR Flow Cytometry Facility for their support, services, and expertise, and Dr John Caldwell for advice on chemical synthesis and O2H Group for batch synthesis of the Abd degrader compounds.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alfieri</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Barford</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Visualizing the complex functions and mechanisms of the anaphase promoting complex/cyclosome (APC/C)</article-title><source>Open Biology</source><volume>7</volume><elocation-id>170204</elocation-id><pub-id pub-id-type="doi">10.1098/rsob.170204</pub-id><pub-id pub-id-type="pmid">29167309</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barger</surname><given-names>CJ</given-names></name><name><surname>Branick</surname><given-names>C</given-names></name><name><surname>Chee</surname><given-names>L</given-names></name><name><surname>Karpf</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Pan-Cancer analyses reveal genomic features of FOXM1 overexpression in cancer</article-title><source>Cancers</source><volume>11</volume><elocation-id>251</elocation-id><pub-id pub-id-type="doi">10.3390/cancers11020251</pub-id><pub-id pub-id-type="pmid">30795624</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Békés</surname><given-names>M</given-names></name><name><surname>Langley</surname><given-names>DR</given-names></name><name><surname>Crews</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>PROTAC targeted protein degraders: the past is prologue</article-title><source>Nature Reviews Drug Discovery</source><volume>21</volume><fpage>181</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1038/s41573-021-00371-6</pub-id><pub-id pub-id-type="pmid">35042991</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bery</surname><given-names>N</given-names></name><name><surname>Miller</surname><given-names>A</given-names></name><name><surname>Rabbitts</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>3233</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-17022-w</pub-id><pub-id pub-id-type="pmid">32591521</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bery</surname><given-names>N</given-names></name><name><surname>Bataille</surname><given-names>CJR</given-names></name><name><surname>Russell</surname><given-names>A</given-names></name><name><surname>Hayes</surname><given-names>A</given-names></name><name><surname>Raynaud</surname><given-names>F</given-names></name><name><surname>Milhas</surname><given-names>S</given-names></name><name><surname>Anand</surname><given-names>S</given-names></name><name><surname>Tulmin</surname><given-names>H</given-names></name><name><surname>Miller</surname><given-names>A</given-names></name><name><surname>Rabbitts</surname><given-names>TH</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A cell-based screening method using an intracellular antibody for discovering small molecules targeting the translocation protein LMO2</article-title><source>Science Advances</source><volume>7</volume><elocation-id>eabg1950</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.abg1950</pub-id><pub-id pub-id-type="pmid">33837087</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bery</surname><given-names>N</given-names></name><name><surname>Rabbitts</surname><given-names>TH</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>A cell-based screening method using an intracellular antibody for discovering small molecules targeting hard-to-drug proteins</article-title><source>Bio-Protocol</source><volume>12</volume><elocation-id>e4324</elocation-id><pub-id pub-id-type="doi">10.21769/BioProtoc.4324</pub-id><pub-id pub-id-type="pmid">35340285</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boehm</surname><given-names>T</given-names></name><name><surname>Baer</surname><given-names>R</given-names></name><name><surname>Lavenir</surname><given-names>I</given-names></name><name><surname>Forster</surname><given-names>A</given-names></name><name><surname>Waters</surname><given-names>JJ</given-names></name><name><surname>Nacheva</surname><given-names>E</given-names></name><name><surname>Rabbitts</surname><given-names>TH</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>The mechanism of chromosomal translocation t(11;14) involving the T-cell receptor C delta locus on human chromosome 14q11 and a transcribed region of chromosome 11p15</article-title><source>The EMBO Journal</source><volume>7</volume><fpage>385</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1988.tb02825.x</pub-id><pub-id pub-id-type="pmid">3259177</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boehm</surname><given-names>T</given-names></name><name><surname>Foroni</surname><given-names>L</given-names></name><name><surname>Kaneko</surname><given-names>Y</given-names></name><name><surname>Perutz</surname><given-names>MF</given-names></name><name><surname>Rabbitts</surname><given-names>TH</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>The rhombotin family of cysteine-rich LIM-domain oncogenes: distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13</article-title><source>PNAS</source><volume>88</volume><fpage>4367</fpage><lpage>4371</lpage><pub-id pub-id-type="doi">10.1073/pnas.88.10.4367</pub-id><pub-id pub-id-type="pmid">2034676</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bond</surname><given-names>MJ</given-names></name><name><surname>Crews</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation</article-title><source>RSC Chemical Biology</source><volume>2</volume><fpage>725</fpage><lpage>742</lpage><pub-id pub-id-type="doi">10.1039/d1cb00011j</pub-id><pub-id pub-id-type="pmid">34212149</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buckley</surname><given-names>DL</given-names></name><name><surname>Van Molle</surname><given-names>I</given-names></name><name><surname>Gareiss</surname><given-names>PC</given-names></name><name><surname>Tae</surname><given-names>HS</given-names></name><name><surname>Michel</surname><given-names>J</given-names></name><name><surname>Noblin</surname><given-names>DJ</given-names></name><name><surname>Jorgensen</surname><given-names>WL</given-names></name><name><surname>Ciulli</surname><given-names>A</given-names></name><name><surname>Crews</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1α interaction</article-title><source>Journal of the American Chemical Society</source><volume>134</volume><fpage>4465</fpage><lpage>4468</lpage><pub-id pub-id-type="doi">10.1021/ja209924v</pub-id><pub-id pub-id-type="pmid">22369643</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burslem</surname><given-names>GM</given-names></name><name><surname>Crews</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Proteolysis-targeting chimeras as therapeutics and tools for biological discovery</article-title><source>Cell</source><volume>181</volume><fpage>102</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.11.031</pub-id><pub-id pub-id-type="pmid">31955850</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cleary</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Oncogenic conversion of transcription factors by chromosomal translocations</article-title><source>Cell</source><volume>66</volume><fpage>619</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(91)90105-8</pub-id><pub-id pub-id-type="pmid">1878967</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deiana</surname><given-names>A</given-names></name><name><surname>Forcelloni</surname><given-names>S</given-names></name><name><surname>Porrello</surname><given-names>A</given-names></name><name><surname>Giansanti</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Intrinsically disordered proteins and structured proteins with intrinsically disordered regions have different functional roles in the cell</article-title><source>PLOS ONE</source><volume>14</volume><elocation-id>e0217889</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0217889</pub-id><pub-id pub-id-type="pmid">31425549</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>WF</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>QL</given-names></name><name><surname>Munroe</surname><given-names>D</given-names></name><name><surname>Minowada</surname><given-names>J</given-names></name><name><surname>Housman</surname><given-names>DE</given-names></name><name><surname>Minden</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Molecular characterization of a chromosome translocation breakpoint t(11;14)(p13;q11) from the cell line KOPT-K1</article-title><source>Leukemia</source><volume>9</volume><fpage>1812</fpage><lpage>1817</lpage><pub-id pub-id-type="pmid">7475267</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Omari</surname><given-names>K</given-names></name><name><surname>Hoosdally</surname><given-names>SJ</given-names></name><name><surname>Tuladhar</surname><given-names>K</given-names></name><name><surname>Karia</surname><given-names>D</given-names></name><name><surname>Hall-Ponselé</surname><given-names>E</given-names></name><name><surname>Platonova</surname><given-names>O</given-names></name><name><surname>Vyas</surname><given-names>P</given-names></name><name><surname>Patient</surname><given-names>R</given-names></name><name><surname>Porcher</surname><given-names>C</given-names></name><name><surname>Mancini</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Structural basis for LMO2-driven recruitment of the SCL:E47bHLH heterodimer to hematopoietic-specific transcriptional targets</article-title><source>Cell Reports</source><volume>4</volume><fpage>135</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2013.06.008</pub-id><pub-id pub-id-type="pmid">23831025</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farnaby</surname><given-names>W</given-names></name><name><surname>Koegl</surname><given-names>M</given-names></name><name><surname>Roy</surname><given-names>MJ</given-names></name><name><surname>Whitworth</surname><given-names>C</given-names></name><name><surname>Diers</surname><given-names>E</given-names></name><name><surname>Trainor</surname><given-names>N</given-names></name><name><surname>Zollman</surname><given-names>D</given-names></name><name><surname>Steurer</surname><given-names>S</given-names></name><name><surname>Karolyi-Oezguer</surname><given-names>J</given-names></name><name><surname>Riedmueller</surname><given-names>C</given-names></name><name><surname>Gmaschitz</surname><given-names>T</given-names></name><name><surname>Wachter</surname><given-names>J</given-names></name><name><surname>Dank</surname><given-names>C</given-names></name><name><surname>Galant</surname><given-names>M</given-names></name><name><surname>Sharps</surname><given-names>B</given-names></name><name><surname>Rumpel</surname><given-names>K</given-names></name><name><surname>Traxler</surname><given-names>E</given-names></name><name><surname>Gerstberger</surname><given-names>T</given-names></name><name><surname>Schnitzer</surname><given-names>R</given-names></name><name><surname>Petermann</surname><given-names>O</given-names></name><name><surname>Greb</surname><given-names>P</given-names></name><name><surname>Weinstabl</surname><given-names>H</given-names></name><name><surname>Bader</surname><given-names>G</given-names></name><name><surname>Zoephel</surname><given-names>A</given-names></name><name><surname>Weiss-Puxbaum</surname><given-names>A</given-names></name><name><surname>Ehrenhöfer-Wölfer</surname><given-names>K</given-names></name><name><surname>Wöhrle</surname><given-names>S</given-names></name><name><surname>Boehmelt</surname><given-names>G</given-names></name><name><surname>Rinnenthal</surname><given-names>J</given-names></name><name><surname>Arnhof</surname><given-names>H</given-names></name><name><surname>Wiechens</surname><given-names>N</given-names></name><name><surname>Wu</surname><given-names>M-Y</given-names></name><name><surname>Owen-Hughes</surname><given-names>T</given-names></name><name><surname>Ettmayer</surname><given-names>P</given-names></name><name><surname>Pearson</surname><given-names>M</given-names></name><name><surname>McConnell</surname><given-names>DB</given-names></name><name><surname>Ciulli</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design</article-title><source>Nature Chemical Biology</source><volume>15</volume><fpage>672</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1038/s41589-019-0294-6</pub-id><pub-id pub-id-type="pmid">31178587</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larson</surname><given-names>RC</given-names></name><name><surname>Lavenir</surname><given-names>I</given-names></name><name><surname>Larson</surname><given-names>TA</given-names></name><name><surname>Baer</surname><given-names>R</given-names></name><name><surname>Warren</surname><given-names>AJ</given-names></name><name><surname>Wadman</surname><given-names>I</given-names></name><name><surname>Nottage</surname><given-names>K</given-names></name><name><surname>Rabbitts</surname><given-names>TH</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice</article-title><source>The EMBO Journal</source><volume>15</volume><fpage>1021</fpage><lpage>1027</lpage><pub-id pub-id-type="pmid">8605871</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Layer</surname><given-names>JH</given-names></name><name><surname>Christy</surname><given-names>M</given-names></name><name><surname>Placek</surname><given-names>L</given-names></name><name><surname>Unutmaz</surname><given-names>D</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Davé</surname><given-names>UP</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>LDB1 enforces stability on direct and indirect oncoprotein partners in Leukemia</article-title><source>Molecular and Cellular Biology</source><volume>40</volume><elocation-id>e00652-19</elocation-id><pub-id pub-id-type="doi">10.1128/MCB.00652-19</pub-id><pub-id pub-id-type="pmid">32229578</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Crews</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>PROTACs: past, present and future</article-title><source>Chemical Society Reviews</source><volume>51</volume><fpage>5214</fpage><lpage>5236</lpage><pub-id pub-id-type="doi">10.1039/d2cs00193d</pub-id><pub-id pub-id-type="pmid">35671157</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Zhu</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>LMO2 attenuates tumor growth by targeting the Wnt signaling pathway in breast and colorectal cancer</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>36050</elocation-id><pub-id pub-id-type="doi">10.1038/srep36050</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lobato</surname><given-names>MN</given-names></name><name><surname>Rabbitts</surname><given-names>TH</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Intracellular antibodies and challenges facing their use as therapeutic agents</article-title><source>Trends in Molecular Medicine</source><volume>9</volume><fpage>390</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1016/s1471-4914(03)00163-1</pub-id><pub-id pub-id-type="pmid">13129705</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Fang</surname><given-names>F</given-names></name><name><surname>Guo</surname><given-names>A</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Tao</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Zhuo</surname><given-names>R</given-names></name><name><surname>Chu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Sang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>H</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Pan</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>LMO2 promotes the development of AML through interaction with transcription co-regulator LDB1</article-title><source>Cell Death &amp; Disease</source><volume>14</volume><elocation-id>518</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-023-06039-w</pub-id><pub-id pub-id-type="pmid">37573405</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGuire</surname><given-names>EA</given-names></name><name><surname>Hockett</surname><given-names>RD</given-names></name><name><surname>Pollock</surname><given-names>KM</given-names></name><name><surname>Bartholdi</surname><given-names>MF</given-names></name><name><surname>O’Brien</surname><given-names>SJ</given-names></name><name><surname>Korsmeyer</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>The t(11;14)(p15;q11) in a T-cell acute lymphoblastic leukemia cell line activates multiple transcripts, including Ttg-1, a gene encoding a potential zinc finger protein</article-title><source>Molecular and Cellular Biology</source><volume>9</volume><fpage>2124</fpage><lpage>2132</lpage><pub-id pub-id-type="doi">10.1128/mcb.9.5.2124-2132.1989</pub-id><pub-id pub-id-type="pmid">2501659</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osada</surname><given-names>H</given-names></name><name><surname>Grutz</surname><given-names>G</given-names></name><name><surname>Axelson</surname><given-names>H</given-names></name><name><surname>Forster</surname><given-names>A</given-names></name><name><surname>Rabbitts</surname><given-names>TH</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Association of erythroid transcription factors: complexes involving the LIM protein RBTN2 and the zinc-finger protein GATA1</article-title><source>PNAS</source><volume>92</volume><fpage>9585</fpage><lpage>9589</lpage><pub-id pub-id-type="doi">10.1073/pnas.92.21.9585</pub-id><pub-id pub-id-type="pmid">7568177</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pagliaro</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>SJ</given-names></name><name><surname>Herranz</surname><given-names>D</given-names></name><name><surname>Mecucci</surname><given-names>C</given-names></name><name><surname>Harrison</surname><given-names>CJ</given-names></name><name><surname>Mullighan</surname><given-names>CG</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Boissel</surname><given-names>N</given-names></name><name><surname>Winter</surname><given-names>SS</given-names></name><name><surname>Roti</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Acute lymphoblastic leukaemia</article-title><source>Nature Reviews. Disease Primers</source><volume>10</volume><elocation-id>41</elocation-id><pub-id pub-id-type="doi">10.1038/s41572-024-00525-x</pub-id><pub-id pub-id-type="pmid">38871740</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paiva</surname><given-names>SL</given-names></name><name><surname>Crews</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Targeted protein degradation: elements of PROTAC design</article-title><source>Current Opinion in Chemical Biology</source><volume>50</volume><fpage>111</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/j.cbpa.2019.02.022</pub-id><pub-id pub-id-type="pmid">31004963</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quevedo</surname><given-names>CE</given-names></name><name><surname>Cruz-Migoni</surname><given-names>A</given-names></name><name><surname>Bery</surname><given-names>N</given-names></name><name><surname>Miller</surname><given-names>A</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Petch</surname><given-names>D</given-names></name><name><surname>Bataille</surname><given-names>CJR</given-names></name><name><surname>Lee</surname><given-names>LYW</given-names></name><name><surname>Fallon</surname><given-names>PS</given-names></name><name><surname>Tulmin</surname><given-names>H</given-names></name><name><surname>Ehebauer</surname><given-names>MT</given-names></name><name><surname>Fernandez-Fuentes</surname><given-names>N</given-names></name><name><surname>Russell</surname><given-names>AJ</given-names></name><name><surname>Carr</surname><given-names>SB</given-names></name><name><surname>Phillips</surname><given-names>SEV</given-names></name><name><surname>Rabbitts</surname><given-names>TH</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>3169</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-05707-2</pub-id><pub-id pub-id-type="pmid">30093669</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabbitts</surname><given-names>TH</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Translocations, master genes, and differences between the origins of acute and chronic leukemias</article-title><source>Cell</source><volume>67</volume><fpage>641</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(91)90057-6</pub-id><pub-id pub-id-type="pmid">1934065</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabbitts</surname><given-names>TH</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Commonality but diversity in cancer gene fusions</article-title><source>Cell</source><volume>137</volume><fpage>391</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.04.034</pub-id><pub-id pub-id-type="pmid">19410533</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Remillard</surname><given-names>D</given-names></name><name><surname>Buckley</surname><given-names>DL</given-names></name><name><surname>Paulk</surname><given-names>J</given-names></name><name><surname>Brien</surname><given-names>GL</given-names></name><name><surname>Sonnett</surname><given-names>M</given-names></name><name><surname>Seo</surname><given-names>H-S</given-names></name><name><surname>Dastjerdi</surname><given-names>S</given-names></name><name><surname>Wühr</surname><given-names>M</given-names></name><name><surname>Dhe-Paganon</surname><given-names>S</given-names></name><name><surname>Armstrong</surname><given-names>SA</given-names></name><name><surname>Bradner</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Degradation of the BAF complex factor BRD9 by heterobifunctional ligands</article-title><source>Angewandte Chemie</source><volume>56</volume><fpage>5738</fpage><lpage>5743</lpage><pub-id pub-id-type="doi">10.1002/anie.201611281</pub-id><pub-id pub-id-type="pmid">28418626</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowley</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Genetics: a story of swapped ends</article-title><source>Science</source><volume>340</volume><fpage>1412</fpage><lpage>1413</lpage><pub-id pub-id-type="doi">10.1126/science.1241318</pub-id><pub-id pub-id-type="pmid">23788787</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Royer-Pokora</surname><given-names>B</given-names></name><name><surname>Loos</surname><given-names>U</given-names></name><name><surname>Ludwig</surname><given-names>WD</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>TTG-2, a new gene encoding a cysteine-rich protein with the LIM motif, is overexpressed in acute T-cell leukaemia with the t(11;14)(p13;q11)</article-title><source>Oncogene</source><volume>6</volume><fpage>1887</fpage><lpage>1893</lpage><pub-id pub-id-type="pmid">1923511</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakamoto</surname><given-names>KM</given-names></name><name><surname>Kim</surname><given-names>KB</given-names></name><name><surname>Kumagai</surname><given-names>A</given-names></name><name><surname>Mercurio</surname><given-names>F</given-names></name><name><surname>Crews</surname><given-names>CM</given-names></name><name><surname>Deshaies</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation</article-title><source>PNAS</source><volume>98</volume><fpage>8554</fpage><lpage>8559</lpage><pub-id pub-id-type="doi">10.1073/pnas.141230798</pub-id><pub-id pub-id-type="pmid">11438690</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sewell</surname><given-names>H</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>El Omari</surname><given-names>K</given-names></name><name><surname>Mancini</surname><given-names>EJ</given-names></name><name><surname>Cruz</surname><given-names>A</given-names></name><name><surname>Fernandez-Fuentes</surname><given-names>N</given-names></name><name><surname>Chambers</surname><given-names>J</given-names></name><name><surname>Rabbitts</surname><given-names>TH</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Conformational flexibility of the oncogenic protein LMO2 primes the formation of the multi-protein transcription complex</article-title><source>Scientific Reports</source><volume>4</volume><elocation-id>3643</elocation-id><pub-id pub-id-type="doi">10.1038/srep03643</pub-id><pub-id pub-id-type="pmid">24407558</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sialana</surname><given-names>FJ</given-names></name><name><surname>Roumeliotis</surname><given-names>TI</given-names></name><name><surname>Bouguenina</surname><given-names>H</given-names></name><name><surname>Chan Wah Hak</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Caldwell</surname><given-names>J</given-names></name><name><surname>Collins</surname><given-names>I</given-names></name><name><surname>Chopra</surname><given-names>R</given-names></name><name><surname>Choudhary</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>SimPLIT: simplified sample preparation for large-scale isobaric tagging proteomics</article-title><source>Journal of Proteome Research</source><volume>21</volume><fpage>1842</fpage><lpage>1856</lpage><pub-id pub-id-type="doi">10.1021/acs.jproteome.2c00092</pub-id><pub-id pub-id-type="pmid">35848491</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Gillette</surname><given-names>MA</given-names></name><name><surname>Paulovich</surname><given-names>A</given-names></name><name><surname>Pomeroy</surname><given-names>SL</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>PNAS</source><volume>102</volume><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id><pub-id pub-id-type="pmid">16199517</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Sewell</surname><given-names>H</given-names></name><name><surname>Waters</surname><given-names>S</given-names></name><name><surname>Phillips</surname><given-names>SEV</given-names></name><name><surname>Rabbitts</surname><given-names>TH</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Single domain intracellular antibodies from diverse libraries: emphasizing dual functions of LMO2 protein interactions using a single VH domain</article-title><source>The Journal of Biological Chemistry</source><volume>286</volume><fpage>3707</fpage><lpage>3716</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.188193</pub-id><pub-id pub-id-type="pmid">20980262</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>KL</given-names></name><name><surname>Bouguenina</surname><given-names>H</given-names></name><name><surname>Miller</surname><given-names>DSJ</given-names></name><name><surname>Sialana</surname><given-names>FJ</given-names></name><name><surname>Hayhow</surname><given-names>TG</given-names></name><name><surname>Choudhary</surname><given-names>JS</given-names></name><name><surname>Rossanese</surname><given-names>OW</given-names></name><name><surname>Bellenie</surname><given-names>BR</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Degradation by design: new cyclin k degraders from old CDK inhibitors</article-title><source>ACS Chemical Biology</source><volume>19</volume><fpage>173</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1021/acschembio.3c00616</pub-id><pub-id pub-id-type="pmid">38193430</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tse</surname><given-names>E</given-names></name><name><surname>Rabbitts</surname><given-names>TH</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Intracellular antibody-caspase-mediated cell killing: an approach for application in cancer therapy</article-title><source>PNAS</source><volume>97</volume><fpage>12266</fpage><lpage>12271</lpage><pub-id pub-id-type="doi">10.1073/pnas.97.22.12266</pub-id><pub-id pub-id-type="pmid">11050246</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wadman</surname><given-names>IA</given-names></name><name><surname>Osada</surname><given-names>H</given-names></name><name><surname>Grütz</surname><given-names>GG</given-names></name><name><surname>Agulnick</surname><given-names>AD</given-names></name><name><surname>Westphal</surname><given-names>H</given-names></name><name><surname>Forster</surname><given-names>A</given-names></name><name><surname>Rabbitts</surname><given-names>TH</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins</article-title><source>The EMBO Journal</source><volume>16</volume><fpage>3145</fpage><lpage>3157</lpage><pub-id pub-id-type="doi">10.1093/emboj/16.11.3145</pub-id><pub-id pub-id-type="pmid">9214632</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warren</surname><given-names>AJ</given-names></name><name><surname>Colledge</surname><given-names>WH</given-names></name><name><surname>Carlton</surname><given-names>MB</given-names></name><name><surname>Evans</surname><given-names>MJ</given-names></name><name><surname>Smith</surname><given-names>AJ</given-names></name><name><surname>Rabbitts</surname><given-names>TH</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>The oncogenic cysteine-rich LIM domain protein rbtn2 is essential for erythroid development</article-title><source>Cell</source><volume>78</volume><fpage>45</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(94)90571-1</pub-id><pub-id pub-id-type="pmid">8033210</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>S</given-names></name><name><surname>Shimosato</surname><given-names>Y</given-names></name><name><surname>Kameya</surname><given-names>T</given-names></name><name><surname>Kuroki</surname><given-names>M</given-names></name><name><surname>Kitahara</surname><given-names>T</given-names></name><name><surname>Minato</surname><given-names>K</given-names></name><name><surname>Shimoyama</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1978">1978</year><article-title>Leukemic distribution of a human acute lymphocytic leukemia cell line (Ichikawa strain) in nude mice conditioned with whole-body irradiation</article-title><source>Cancer Research</source><volume>38</volume><fpage>3494</fpage><lpage>3498</lpage><pub-id pub-id-type="pmid">278639</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>DL</given-names></name><name><surname>Look</surname><given-names>AT</given-names></name><name><surname>Melvin</surname><given-names>SL</given-names></name><name><surname>Roberson</surname><given-names>PK</given-names></name><name><surname>Dahl</surname><given-names>G</given-names></name><name><surname>Flake</surname><given-names>T</given-names></name><name><surname>Stass</surname><given-names>S</given-names></name></person-group><year iso-8601-date="1984">1984</year><article-title>New chromosomal translocations correlate with specific immunophenotypes of childhood acute lymphoblastic leukemia</article-title><source>Cell</source><volume>36</volume><fpage>101</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(84)90078-3</pub-id><pub-id pub-id-type="pmid">6607116</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winter</surname><given-names>GP</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Antibody engineering</article-title><source>Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences</source><volume>324</volume><fpage>537</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1098/rstb.1989.0066</pub-id><pub-id pub-id-type="pmid">2573089</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>Y</given-names></name><name><surname>Warren</surname><given-names>AJ</given-names></name><name><surname>Dobson</surname><given-names>C</given-names></name><name><surname>Forster</surname><given-names>A</given-names></name><name><surname>Pannell</surname><given-names>R</given-names></name><name><surname>Rabbitts</surname><given-names>TH</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis</article-title><source>PNAS</source><volume>95</volume><fpage>3890</fpage><lpage>3895</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.7.3890</pub-id><pub-id pub-id-type="pmid">9520463</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>Y</given-names></name><name><surname>Pannell</surname><given-names>R</given-names></name><name><surname>Forster</surname><given-names>A</given-names></name><name><surname>Rabbitts</surname><given-names>TH</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The oncogenic LIM-only transcription factor Lmo2 regulates angiogenesis but not vasculogenesis in mice</article-title><source>PNAS</source><volume>97</volume><fpage>320</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1073/pnas.97.1.320</pub-id><pub-id pub-id-type="pmid">10618416</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>Y</given-names></name><name><surname>Zhong</surname><given-names>Y</given-names></name><name><surname>Miki</surname><given-names>S</given-names></name><name><surname>Taura</surname><given-names>A</given-names></name><name><surname>Rabbitts</surname><given-names>TH</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The transcription factor complex LMO2/TAL1 regulates branching and endothelial cell migration in sprouting angiogenesis</article-title><source>Scientific Reports</source><volume>12</volume><elocation-id>7226</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-022-11297-3</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>T</given-names></name><name><surname>Lin</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The involvement of ubiquitination machinery in cell cycle regulation and cancer progression</article-title><source>International Journal of Molecular Sciences</source><volume>22</volume><elocation-id>5754</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22115754</pub-id><pub-id pub-id-type="pmid">34072267</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.106699.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cooper</surname><given-names>Jonathan A</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Fred Hutch Cancer Center</institution><country>United States</country></aff></contrib></contrib-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group><kwd-group kwd-group-type="evidence-strength"><kwd>Solid</kwd></kwd-group></front-stub><body><p>This <bold>important</bold> paper reports the development of proteins and small molecules that induce degradation of a clinically-relevant oncogenic transcription factor, LMO2. The findings provide a proof of concept that PROTAC-type chemicals can be developed against intrinsically disordered proteins. The methods provide a blueprint for rational design of PROTACs starting from intracellular antibody paratopes. Overall, the paper is supported by <bold>solid</bold> evidence and will be of interest to chemical biologists and cancer pharmacologists.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.106699.3.sa1</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>Sereesongsaeng et al. aimed to develop degraders for LMO2, an intrinsically disordered transcription factor activated by chromosomal translocation in T-ALL. The authors first focused on developing biodegraders, which are fusions of an anti-LMO2 intracellular domain antibody (iDAb) with cereblon. Following demonstrations of degradation and collateral degradation of associated proteins with biodegraders, the authors proceeded to develop PROTACs using antibody paratopes (Abd) that recruit VHL (Abd-VHL) or cereblon (Abd-CRBN). The authors show dose-dependent degradation of LMO2 in LMO2+ T-ALL cell lines, as well as concomitant dose-dependent degradation of associated bHLH proteins in the DNA-binding complex. LMO2 degradation via Abd-VHL was also determined to inhibit proliferation and induce apoptosis in LMO2+ T-ALL cell lines.</p><p>Strengths:</p><p>The topic of degrader development for intrinsically disordered proteins is of high interest and the authors aimed to tackle a difficult drug target. The authors evaluated methods including the development of biodegraders, as well as PROTACs that recruit two different E3 ligases. The study includes important chemical control experiments, as well as proteomic profiling to evaluate selectivity.</p><p>Weaknesses:</p><p>Several weaknesses remain in this study:</p><p>(1) The overall degradation achieved is not highly potent (although important proof-of-concept);</p><p>(2) The mechanism of collateral degradation is not completely addressed. The authors acknowledge possible explanations, which would require mutagenesis and structural studies to further dissect;</p><p>(3) The proteomics experiments do not detect LMO2, which the authors attribute to its size, making it difficult to interpret.</p></body></sub-article><sub-article article-type="author-comment" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.106699.3.sa2</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sereesongsaeng</surname><given-names>Naphannop</given-names></name><role specific-use="author">Author</role><aff><institution>Institute of Cancer Research</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Bataille</surname><given-names>Carole</given-names></name><role specific-use="author">Author</role><aff><institution>University of Oxford</institution><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Russell</surname><given-names>Angela</given-names></name><role specific-use="author">Author</role><aff><institution>Univeristy of Oxford</institution><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Bery</surname><given-names>Nicolas</given-names></name><role specific-use="author">Author</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/003412r28</institution-id><institution>Centre de Recherche en Cancérologie de Toulouse</institution></institution-wrap><addr-line><named-content content-type="city">Toulouse</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Sialana</surname><given-names>Fernando J</given-names></name><role specific-use="author">Author</role><aff><institution>Institute of Cancer Research</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Choudhary</surname><given-names>Jyoti</given-names></name><role specific-use="author">Author</role><aff><institution>Institute of Cancer Research</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Miller</surname><given-names>Ami</given-names></name><role specific-use="author">Author</role><aff><institution>Evotec</institution><addr-line><named-content content-type="city">Abingdon</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Rabbitts</surname><given-names>Terence</given-names></name><role specific-use="author">Author</role><aff><institution>Institute of Cancer Research</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Public review):</bold></p><p>Summary:</p><p>The authors describe the degradation of an intrinsically disordered transcription factor (LMO2) via PROTACs (VHL and CRBN) in T-ALL cells. Given the challenges of drugging transcription factors, I find the work solid and a significant scientific contribution to the field.</p><p>Strengths:</p><p>(1) Validation of LMO2 degradation by starting with biodegraders, then progressing to chemical degrades.</p><p>(2)interrogation of the biology and downstream pathways upon LMO2 degradation collateral degradation §</p><p>(3) Cell line models that are dependent/overexpression of LMO2 vs LMO2 null cell lines.</p><p>(4) CRBN and VHL-derived PROTACs were synthesized and evaluated.</p><p>Weaknesses:</p><p>(1) The conventional method used to characterize PROTACs in the literature is to calculate the DC50 and Dmax of the degraders, I did not find this information in the manuscript.</p></disp-quote><p>As noted in the reply to referee’s point 4 below, our first generation compounds are not highly potent. The DC<sub>50</sub> values have been computed specifically using Western blot reflected in the data shown in Fig. 2. The revised version Supplementary Fig. S3 shows these quantified Western blot data from a time course of treating KOPT-K1 cells with either Abd-CRBN and Abd-VHL, where the 24 hour blot data are shown in Figure 2, G and E, and the quantified data from each 24 hour treatment are quantified in Supplementary Fig. S3. With these data, the DC<sub>50</sub> values 9 μM for Abd-CRBN and 15 μM Abd-VHL, included in in the main text and the Supplementary Fig. S3 figure legend.</p><p>In addition, the loss of signal of the LMO2-Rluc reporter protein from PROTAC treated cells shown in Fig. 2M has been used to calculate a half-point of degradation; although strictly not DC<sub>50</sub>, as it measures a reporter protein, this yielded values are 10 μM for Abd-CRBN and 9 μM Abd-VHL.</p><disp-quote content-type="editor-comment"><p>(2) The proteomics data is not very convincing, and it is not clear why LMO2 does not show in the volcano plot (were higher concentrations of the PROTAC tested? and why only VHL was tested and not CRBN-based PROTAC?).</p></disp-quote><p>Due to the relatively small size of the LMO2 protein, it is challenging to produce enough unique peptides for reliable identification, especially to distinguish some proteins in the LMO2 complex.</p><disp-quote content-type="editor-comment"><p>(3) The correlation between degradation potency and cell growth is not well-established (compare Figure 4C: P12-Ichikawa blots show great degradation at 24 and 48 hrs, but it is unclear if the cell growth in this cell line is any better than in PF-382 or MOLT-16) - Can the authors comment on the correlation between degradation and cell growth?</p></disp-quote><p>In this study (Fig. 4) we did not aim to compare the effect of LMO2 loss on cell growth among LMO2 positive cells. Rather, we aimed to evaluate the LMO2 importance for cell growth in LMO2-expressing T-ALL cells compared to non-expressing cells and to correlate the loss of the protein with this effect on the cell growth. In addition, the treatment of cells with the LMO2 compounds did now show an effect to LMO2 negative cells until at least 48 hours of treatment indicating that low toxicity of our PROTAC compounds and providing correlation between LMO2 loss and cell growth.</p><disp-quote content-type="editor-comment"><p>(4) The PROTACs are not very potent (double-digit micromolar range?) - can the authors elaborate on any challenges in the optimization of the degradation potency?</p></disp-quote><p>The Abd methodology to use intracellular domain antibodies to screen for compounds that bind to intrinsically disordered proteins such as the LMO2 transcription factors offers a tractable approach to hard drug targets but, in so doing, creates challenging factors to improve the potency that are not the same as those targets for which structural data are available. LMO2 is an intrinsically disordered protein, for which soluble recombinant protein is not readily available to identify the binding pocket of compounds. The potency has so far been optimized solely based on the different moieties substituted in cell-based SAR studies <ext-link ext-link-type="uri" xlink:href="http://advances.sciencemag.org/cgi/content/full/7/15/eabg1950/DC1">(</ext-link><ext-link ext-link-type="uri" xlink:href="http://advances.sciencemag.org/cgi/content/full/7/15/eabg1950/DC1">http://advances.sciencemag.org/cgi/content/full/7/15/eabg1950/DC1</ext-link><ext-link ext-link-type="uri" xlink:href="http://advances.sciencemag.org/cgi/content/full/7/15/eabg1950/DC1">)</ext-link> and all new compounds were tested with BRET assays. Thus, currently optimization of the degradation potency (including properties such as improved solubility) for the LMO2-binding compounds relies on chemical modification the three areas of the compounds indicated in Fig. 2 B,C.</p><disp-quote content-type="editor-comment"><p>(5) The authors mentioned trying six iDAb-E3 ligase proteins; I would recommend listing the E3 ligases tried and commenting on the results in the main text.</p></disp-quote><p>The six chimaeric iDAb-E3 ligase proteins involved one anti-LMO2 iDAb and three different E3 ligase where either fused at the N- or the C-terminus of the VH (giving six protein formats). These six fusion proteins were described in the text referring to the degrader studies described in Supplementary Fig. 1.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public review):</bold></p><p>Summary:</p><p>Sereesongsaeng et al. aimed to develop degraders for LMO2, an intrinsically disordered transcription factor activated by chromosomal translocation in T-ALL. The authors first focused on developing biodegraders, which are fusions of an anti-LMO2 intracellular domain antibody (iDAb) with cereblon. Following demonstrations of degradation and collateral degradation of associated proteins with biodegraders, the authors proceeded to develop PROTACs using antibody paratopes (Abd) that recruit VHL (Abd-VHL) or cereblon (Abd-CRBN). The authors show dose-dependent degradation of LMO2 in LMO2+ T-ALL cell lines, as well as concomitant dose-dependent degradation of associated bHLH proteins in the DNA-binding complex. LMO2 degradation via Abd-VHL was also determined to inhibit proliferation and induce apoptosis in LMO2+ T-ALL cell lines.</p><p>Strengths:</p><p>The topic of degrader development for intrinsically disordered proteins is of high interest, and the authors aimed to tackle a difficult drug target. The authors evaluated methods, including the development of biodegraders, as well as PROTACs that recruit two different E3 ligases. The study includes important chemical control experiments, as well as proteomic profiling to evaluate selectivity.</p><p>Weaknesses:</p><p>The overall degradation is relatively weak, and the mechanism of potential collateral degradation is not thoroughly evaluated</p></disp-quote><p>The purpose of the study was to evaluate effects of LMO2 degraders. The mechanism of the observed collateral degradation could not be investigated directly within the scope of our study. In the main text, discussed two possible, not exclusive, explanations. One being that our work (and previously published, cited work) indicates that the DNA-binding bHLH proteins have relatively short half file (Supplementary Fig. S12) and may therefore be subject to normal turnover when the LMO2, which is in the complex, turns over. Further, the known structure of the LMO2-bHLH interactions (from Omari et al, doi: 10.1016/j.celrep.2013.06.008) was also examined for the location of lysines in the TAL1 &amp; E47 partners (Supplementary Fig. S11). It is possible that their local association with the LMO2-E3-ligase complex created by the PROTAC interaction, could cause their concurrent degradation. Mutagenesis and structural analysis would be needed to establish this point.</p><disp-quote content-type="editor-comment"><p>In addition, experiments comparing the authors' prior work with their anti-LMO2 iDAb or Abl-L are lacking, which would improve our understanding of the potential advantages of a degrader strategy for LMO2.</p></disp-quote><p>A major motivation behind developing the Antibody-derived (Abd) method to select compounds, which are surrogates of the antibody paratope, is because using iDAbs directly as inhibitors requires the development of delivery technologies for these macromolecules, as protein directly or as vectors or mRNA for their expression. Ultimately, high affinity anti-LMO2 iDAbs should directly be used as tractable inhibitors when delivery methods redeveloped. In the meantime, Abd compounds were envisaged as being surrogates suitable for development into reagents, and potentially drugs, by medicinal chemistry. We evaluated selected first generation LMO2-binding Abd compounds previously, finding their ability to interfere with LMO2-iDAb BRET signal to EC<sub>max</sub> about 50% but these compounds do not have potency to have an effect on the interaction of LMO2 with a non-mutated iDAb (nM affinity). These data indicated that efficacy improvement for the PROTACs was needed. In addition, in the current study, we observed viability effects in T-ALL lines at high concentrations (20 μM) irrespective of LMO2 expression (Supplementary Fig. S 2A, B) These data indicated that efficacy improvement was needed and potentially converting the degraders (PROTACs) would add to in-cell potency. By adding the E3 ligase ligands, we found the toxicity of non-LMO2 expressing Jurkat was significantly reduced (Supplementary Fig. S 2E, F).</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations for the authors):</bold></p><p>Suggestions for additional experiments:</p><p>(1) The data presented is primarily focused on demonstrating targeted degradation of LMO2, with a focus on phenotypes such as proliferation and apoptosis. In this manuscript, there are limited comparative evaluations of anti-LMO2 iDAb or Abl-L to show the potential benefits of a degrader approach to their previously described work, as well as why targeted degradation is in fact, advantageous. For example, the authors' previous work has shown that anti-LMO2 iDAb inhibits tumor growth in a mouse transplantation model. Comparisons in vitro would be supportive of the importance of continued degrader optimization/development.</p></disp-quote><p>we have previously shown that an anti-LMO2 scFv inhibits tumour growth in a mouse model but this work used an expressed scFv antibody that binds to LMO2 in nM range. The Abd compounds are much lower potency that the antibody and, because recombinant LMO2 is difficult to work with, we could only evaluate interactions of compounds with LMO2 in cell-based assays like BRET (LMO2-iDAb BRET). In this cell-based assay, the first generation Abd compounds do not have sufficient potency to block LMO2-iDAb interaction unless the affinity of the iDAb is reduced to sub-μM. The justification for proceeding on the degrader process rather than just using the protein-protein interaction (PPI) inhibition was based largely around the low potency of the first generation PPI compounds in cell assays and that incorporation protein degradation with PPI inhibition would enhance the efficacy.</p><disp-quote content-type="editor-comment"><p>In addition, the viability experiments are also very short-term; is there a reason why the authors did not carry out these experiments for 3-5 days to fully understand the impacts on proliferation?</p></disp-quote><p>In Supplementary Fig. S5, we did show assays up to 3 days. In KOPT-K1 (LMO2+), the LMO2 levels were reduced during the time course of this assay (from a single compound dose at time zero) (Supplementary Fig S 5A, B). We also show CellTitreGlo assays up to 3 days and, with these second generation compounds, we observed sustained effects on KOPT-K1 (LMO2+) but low non-DMSO toxicity in Jurkat (LMO2-) revised version Supplementary (Fig S5 C, D).</p><disp-quote content-type="editor-comment"><p>(2) The potential mechanism of collateral degradation is interesting and important in evaluating the on-target responses and consequences of degrading LMO2. At this time, the data supporting collateral degradation is limited and would be strengthened by showing that it is not due to a change in mRNA levels and not due to complex dissociation. Overall, the kinetics and depth of loss of complex members such as E47 in Figure 3 appear more substantial than LMO2 itself, and as presented, collateral degradation is not effectively demonstrated. In addition, to aid in the readers' assessments, additional background and references around the roles of TAL1 and E47 would be helpful. For example, structurally, where do they (and other associated proteins that are not degraded) fit in the complex?</p></disp-quote><p>We have responded above in relation to the Public Review Comments and note that a structure of the complex was in submitted version (now revised version Supplementary Fig. S11).</p><disp-quote content-type="editor-comment"><p>(3) In Figure 1A, the blots show decreased levels of endogenous CRBN with iDAB-CRBN. Is this a known consequence of this approach in these cell lines? Does the partial recovery of endogenous CRBN in KOPTK1 cells have any indication of iDAB-CRBN levels?</p></disp-quote><p>We cannot be sure why the endogenous level of CRBN decreases in doxycycline treated cells. It has been shown (DOI:10.1371/journal.pone.0064561) that doxycycline used in the inducible expression system (and its derivatives), such as the lentivirus we used, has an effect to gene expression patterns, which can be increase or decrease expression. Although the published study did not examine CRBN expression, the effect might explain the CRBN expression decrease on doxycycline addition and remains the same level after that.</p><disp-quote content-type="editor-comment"><p>(4) In Figure S7, the authors do not fully explain the results and why there is minimal rescue with epoxomicin (S7A) or MLN4924 (S7J). This could indicate an alternative mechanism of degradation and loss at play, given the lack of rescue. Can the authors comment on this discrepancy, and have they looked autophagy inhibitor or other agents to achieve the chemical rescue?</p></disp-quote><p>In the experiments such as in revised version Supplementary Fig. S6, we used KOPT-K1 cells with a single concentration of the inhibitors and the cells may less susceptible to the epoxomicin (0.8 μM) but lenalidomide and free thalidomide restored the LMO2 levels fully. In the main text Fig. 3D, we also showed that including epoxomicin and thalidomide with the Abd-CRBN in KOPT-K1 and CCRF-CEM restore LMO2 levels, supporting the conclusion that the main mechanism of degradation is through ubiquitination proteosomal route.</p><disp-quote content-type="editor-comment"><p>(5) For the proteomics data, it would be helpful to have the proteins in yellow highlighted to have them noted in 5D and 5E. In addition, can the authors comment on why LMO2 or their collateral targets are not confirmed in the table? Furthermore, 5C is difficult to interpret; if there are no significantly changing proteins in the Jurkat cells, why are there pathways that are identified?</p></disp-quote><p>As mentioned in reply to referee 1, due to the relatively small size of the LMO2 protein, it is challenging to produce enough unique peptides for reliable identification, especially to distinguish some proteins in the LMO2 complex where expression levels are low.</p></body></sub-article></article>